



Prostate Cancer  
Foundation  
Curing Together.

2016 Progress Report



# Prostate Cancer Foundation

Curing Together.

## ABOUT THE COVER

The Prostate Cancer Foundation (PCF), the world leader in prostate cancer research funding, has unveiled a new corporate identity with the tagline “Curing Together.” This refresh represents PCF’s evolution as a patient-centric brand that humanizes science to connect with audiences on a personal level.

## MISSION STATEMENT

PCF funds the world’s most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.

© 2017 Prostate Cancer Foundation

## PCF Launches New, Patient-Centric Brand

PCF’s new tagline, “Curing Together,” reflects a new vision and affirms our commitment to saving lives.

PCF’s new helix-inspired logo signals the Foundation’s emphasis on personalized, genomics-driven precision medicine. A fully redesigned website features a sleek, simplified interface with enhanced capabilities and information to help men at their critical time of need.

Our new public-facing brand will help us bring precision oncology to the global community of men with prostate cancer along with their families, friends, and loved ones. Our goal is to be patient-centric with personal, actionable messaging that improves the lives of all men.

**Curing together, we can change the future.**



[bbb.org/charity](http://bbb.org/charity)

PCF meets all 20 of the Better Business Bureau’s standards for charity accountability.



PCF has been designated a Top-Rated Charity by Charity Watch.

There are several risk factors for prostate cancer, including family history, age, and race. Know your risks for prostate cancer and talk to your doctor about early detection and screening.

|                                                                                                               |    |
|---------------------------------------------------------------------------------------------------------------|----|
| Founder & CEO Letter                                                                                          | 4  |
| When Cancer Takes the Back Roads: New Strategies for Fighting Resistance                                      | 7  |
| Many vs Cancer: The Beginning of the End of Prostate Cancer                                                   | 10 |
| Treating the Gene: A Survivor Story                                                                           | 12 |
| One in Nine Advanced Prostate Cancers are Caused by Heritable Genes                                           | 17 |
| PCF-Veterans Administration Precision Oncology Partnership—A Veterans Health Initiative to Support Our Heroes | 19 |
| Movember Foundation-PCF Partnership                                                                           | 21 |
| 2016 Fundraising Events                                                                                       | 22 |
| Major League Baseball and PCF Make History Together                                                           | 24 |
| A Survivor's Appeal for Support                                                                               | 26 |
| Supporting Cures                                                                                              | 27 |
| 2016 Donor Roll                                                                                               | 28 |
| 2016 Research Awards: Expanding PCF's Global Research Enterprise                                              | 34 |
| 2016 Financials                                                                                               | 38 |
| 2016 Supporting Partners                                                                                      | 42 |
| Board of Directors and Leadership Team                                                                        | 43 |

# Curing Together, We Can Change the Future.

Dear Friends:

When the Prostate Cancer Foundation (PCF) was founded in 1993, we faced a challenge. Roughly one in six men was diagnosed with prostate cancer, and more than 40,000 died each year. With the aging population, the numbers were projected to get much worse. Yet most people knew little about the disease, and research funding was scant. Thanks to your support, that has all changed.

Prostate cancer deaths are down 52%, a full 80% lower than what experts had projected. That translates to 1.5 million men who weren't expected to be with us today but are alive and well.

And thanks to advances in precision oncology, discoveries made in PCF-funded labs

*PCF discoveries now save lives in 16 other forms of cancer, including breast, myeloma, colon, lung, ovarian, melanoma, pediatric neuroblastoma, bladder, and thyroid cancers.*

now extend to saving lives across 16 other forms of cancer. Patients and families everywhere owe an immeasurable debt to PCF's supporters.

## Investing in Human Capital

Since our founding, PCF has awarded more than \$435 million to 5,000+ physician-scientists across 2,000 research programs at 200 cancer centers and universities spanning 19 countries, and we've contributed to every significant discovery in the fight against prostate cancer.

At the same time, each dollar invested in PCF-supported research has been further leveraged by an average of 13 follow-on dollars, largely from federal research agencies and biopharma companies.

But our work isn't finished yet, and the stakes are clear:

- Every 3.3 minutes a man is diagnosed with prostate cancer, and one dies every 20 minutes.
- Prostate cancer continues to affect one in eight American men—and their families—making it the most common non-skin cancer.

- Roughly 161,000 men will be diagnosed this year; 27,000 will die from the disease.
- The U.S. spent \$125 billion on cancer care in 2010 and could spend \$156 billion each year by 2020.

In 2016 alone, PCF funded a global research network spanning 145 physician-scientists, including 26 Young Investigators (YIs) and 74 active Challenge Award teams.

Our YIs have truly changed the course of cancer history. Over the years we've discovered that our most impactful investments have gone to these early-career researchers, many of whom have big, risky ideas that are otherwise difficult to fund. They're the engine of innovation in the field. The 26 YIs in the Class of 2016 bring the total number of PCF YIs to 204. They're collectively pursuing 21 "first-in-field" anti-prostate cancer therapies.

Your support in 2016 also helped launch 20 new PCF Challenge Awards, funding the projects of 119 "Team Science" researchers from 30 institutions in eight countries. These multidisciplinary teams of investigators work on the most crucial unmet needs for advanced prostate cancer patients, and in 2016 they introduced into the clinic 19 first-in-field therapies.

### Serving Those Who Served Us

Prostate cancer is the most frequently diagnosed cancer among United States veterans, accounting for a third of male cases. Roughly 180,000 veterans suffer from the disease, with 12,000 new cases diagnosed each year.

In 2016, PCF partnered with the U.S. Department of Veterans Affairs (VA) for an ambitious five-year, \$50 million program to establish a network of precision oncology Centers of Excellence. This partnership will improve care and increase options for our veteran servicemembers while granting researchers access to troves of voluntary and anonymized patient data, thereby advancing cancer research to benefit patients everywhere.

### Together, We Change the Future

Historians may one day deem 2016 to have been the beginning of the era of precision oncology—a transformative year in which our knowledge base and technological capabilities merged to unlock new ways of approaching cancer research. Today's researchers are using these advances to unlock novel investigational therapies, designed and targeted to each unique form of cancer.

When we founded PCF, prostate cancer was thought of as a single disease. We now know of at least 28 different forms of the cancer. Tumors today are identified by their DNA code and molecular architecture rather than their location in the body. Triple-negative breast cancer, for instance, is more closely related to treatment-resistant prostate cancer than it is to other forms of breast cancer. PCF's work, therefore, generates "collateral benefits." As just one example, if we were able to cure 28% of prostate cancer patients—those with the WNT genetic defect—we would, as a fortunate byproduct, also cure more than 90% of all colon cancer cases.

Precision genomics will lead to clinical decisions based on the unique genetics of an individual

patient's particular disease. The days of long, debilitating trial-and-error to discover which drugs may work are fading—we now know which genes to look for and which drugs will work on them. A PCF research team recently identified 19 targets for precision interventions and is now advancing

*Curing those prostate cancer patients with the WNT genetic defect would also cure more than 90% of colon cancers. Such are the collateral benefits of PCF's leadership in precision oncology.*

treatments to address these targets.

It's not a question of *whether* they will be successful, but *when*.

Given advances in precision oncology, PCF continues to lead the way for other research organizations. It was, after

all, early PCF support of immunology that yielded two FDA-approved treatments for both melanoma and prostate cancer. Four other PCF discoveries now save lives in 16 different forms of cancer, including breast, myeloma, colon, lung, ovarian, melanoma, glioblastoma, pediatric neuroblastoma, bladder, leukemia, and thyroid cancers.

## We Cure Together

We were reminded of our progress together as we honored the 1.5 million more men who were able to celebrate Father's Day this year. We interacted with several of them during our annual Home Run Challenge ballpark tour. Some told us they got to witness their kids' marriages and their grandchildren's births. Some told us about the contributions they've made to society long after they were expected to succumb to disease.

We both feel a deep personal gratitude for your support. One of us, Mike, is a prostate cancer survivor who has lost too many family members to cancer. The other, Jonathan, is the son, grandson, and husband of cancer survivors. We approach our mission systemically, but we're also driven by personal motivation to rid the world of the pain, suffering, and loss caused by cancer.

Your support is crucial to this effort, and it's deeply appreciated by us and by men and their families everywhere.

Thank you,



**Michael Milken**  
Founder and Chairman



**Jonathan W. Simons, MD**  
President and Chief Executive Officer  
David H. Koch Chair



# WHEN CANCER TAKES THE BACK ROADS: New Strategies for Fighting Resistance



Suzanne Conzen, MD, has been doing research on *breast cancer* for 20 years. So why is PCF so excited about funding her work?

Because—thanks largely to PCF-funded research—understanding of **breast cancer and prostate cancer has converged: they share the same genes and pathways.** We now know that pancreatic cancer and colon cancer share genes and pathways with prostate cancer, too.

PCF is funding some of the best and brightest scientists who are working on other forms of cancer because *their discoveries are going to move our understanding of prostate cancer forward.*

The shared target that Suzanne Conzen, a medical oncologist at the University of Chicago, is working on is one that nobody was talking about even two years ago. It is the *glucocorticoid receptor (GR) pathway*, responsible for the stress hormone, cortisol.

What's it doing in prostate cancer? Bad things. Imagine that you're stuck in traffic on the highway. It's a parking lot. Then, you notice movement off to your right—cars moving along unhindered. And you realize, "Hey, there's a frontage road!" Parallel to the highway, this is the back road the locals take. It may not be the four-lane highway, but those cars are getting somewhere, and you're not.

This is pretty similar to what's happening when prostate cancer becomes resistant to the drugs enzalutamide and abiraterone, which target the androgen receptor (AR). *When prostate cancer gets blocked on the AR highway, it simply cuts over to the frontage road and keeps on going.*

The parallel road in this case involves GR. In groundbreaking research over the last two years, with a PCF Challenge Award, Conzen has been exploring GR's role in *sabotaging antiandrogen drugs*. "We discovered that when GR is over-expressed in triple-negative breast cancer, the prognosis is much worse," she says.

**When the GR gets involved, prostate cancer turns ugly, too.** It turns out that AR and GR pathways have an overlapping "cistrome"—a subset of genes controlled by a master switch. When the AR is shut down, GR moves in and occupies some of the exact same places on DNA, switching on and off genes that promote tumor growth.



Suzanne Conzen, MD  
University of Chicago  
2014 Movember Foundation-  
PCF Challenge Award recipient;  
2016 Stewart J. Rahr Foundation-  
PCF Special Challenge Award recipient



The implications of this are huge. What Conzen, co-principal investigator, Russell Szmulewitz, MD, and colleagues are learning *has the potential to transform the care of men with metastatic prostate cancer*. Their hypothesis—that blocking GR could force cancer back on the main road, and make drugs such as enzalutamide work better—is being tested in clinical trials now, in breast cancer as well as prostate cancer. One GR-blocking drug, mifepristone, is already FDA-approved for use in other conditions. Others are in development.

“This is why we are actively funding precision research on GR and other genetic targets,” says PCF President and CEO, Jonathan W. Simons, MD, who is a medical oncologist. “If you have metastatic prostate cancer and you took enzalutamide and had a very short remission—your PSA dropped, and then it came right back—then you probably have a GR-driven tumor.”

If GR activity is one of the major reasons that treatment for metastatic prostate cancer fails—if, as Conzen suspects, it is causing “even more nastiness and proliferation,” and an effective drug can block that activity, “hopefully there will be significantly longer remissions.”

Conzen, Szmulewitz and colleagues are hoping to answer other questions sparked by their discoveries. Among them:

### **1 When does the GR pathway get involved?**

ADT (androgen deprivation therapy, the first-line hormonal therapy for men with metastatic cancer) may trigger this crossover to the bypass road of GR, although some men’s tumors may have very high GR activity even in earlier stages of prostate cancer.

### **2 Could a GR-blocking treatment make a difference in high-risk men before surgery? Could it even alleviate the need for ADT?**

Men whose tumors have a variant androgen receptor (AR), called ARV7, are resistant to enzalutamide and abiraterone. Would blocking GR allow antiandrogens to work in these men?

### **3 Could blocking the GR pathway somehow make immunotherapy more effective?**

A combined study of mifepristone and pembrolizumab, an immunotherapy drug, is being planned for patients with triple-negative breast cancer.

Conzen’s work is “first in field,” says Simons. This means that her findings are really exciting—and that we’re just at the beginning here. If the clinical trials of GR-blocking drugs show as much promise as Conzen, Simons, and PCF hope they will, “we may see use of these drugs as soon as there is a recurrence in PSA after initial treatment, and we may see men who have failed enzalutamide going back into a long-term remission.” 🍷



[manyvscancer.org](http://manyvscancer.org)

## ***A Decisive Moment: The Beginning of the End of Prostate Cancer*** **Many vs Cancer Will Power Prostate Cancer Research to the Finish Line**

For the first time ever, a cure is within our reach. Science has shown us how we will conquer prostate cancer—now we just need to end it once and for all. Thanks to the amazing foresight of PCF's leadership, we know what it will take: one billion dollars to fund the research that will drive this revolution. While that might sound like a lot of money to one person, it's not a lot for **Many**.

**And that's how the idea for **Many vs Cancer** was born.**

Many vs Cancer (MvC), brainchild of PCF board member Andy Astrachan, is set to be the greatest crowd funding effort since the March of Dimes. Many individuals all around the world who have been touched by prostate cancer will rally to raise the funds to do the research that will defeat prostate cancer in just five years. MvC features a peer-to-peer fundraising platform that allows patients, survivors, and the people who love them to be real agents in the fight. After a cancer diagnosis, many people feel powerless to do anything or affect any kind of real change. But with a cure for prostate cancer in our sights, each and every person who participates in MvC will be able to say to that they were part of the movement that ended death from prostate cancer.

### ***A Monumental Moment***

After more than a year of development, PCF's MvC launched in May of 2017. The new branded website and fundraising platform features relatable human interest content and precision medical information written specifically for patients and fundraisers. The peer-to-peer fundraising platform allows the public to take part in fundraising for PCF via a set of state-of-the-art precision crowdfunding tools. **PCF.org** and **manyvscancer.org** share content across platforms and audience members.

MvC marketing campaigns are designed to steadily bring new audiences of donors to PCF, while also developing an acquisition channel for prospective major gift donors who might otherwise have never heard of PCF. When they visit **manyvscancer.org**, people have the option of becoming a fundraiser or making a direct donation.



1

Donate, and 100% will go to the Prostate Cancer Foundation.

2

Fundraise in honor of a patient you love.

3

Challenge your friends and family to join you.

MvC supporters are able to host any sort of DIY (do-it-yourself) fundraiser for PCF—from hosting car shows to wine parties, BBQs to golf games—while simultaneously honoring the men in their lives who have struggled with prostate cancer.

With the thought that a shared goal is a more powerful goal, MvC has also created affinity groups to help people find others in similar careers, life situations or interest groups: Many Patients vs Cancer, Many Daughters vs Cancer, Many Classic Car Lovers vs Cancer, and so on. MvC's new team of in-house fundraising and marketing specialists are on hand to closely manage our community and to cultivate one-off donors into long-term fundraisers.

### **Curefunding is the New Crowdfunding**

According to the latest industry figures, the top 30 crowdfunding foundations raised \$1.57 billion in 2016. Passionate, motivated individuals raised money from walks, runs, bikes, DIY campaigns, and virtual events through non-profit peer-to-peer fundraising platforms. The market for peer-to-peer fundraising continues to grow and MvC will open a new line of donations for the Prostate Cancer Foundation.

Starting in 2017 MvC will run various smaller campaigns to mobilize fundraising around specific themes, such as Father's Day, Prostate Cancer Awareness Month, and End of Year. MvC will also create innovative "CureFunding" campaigns to give the public the opportunity to directly invest in and follow specific investigators, teams, and research areas.

Together, we are building the greatest crowdfunding effort the world has ever seen—and we are going to cure a disease that affects 14 million men around the world and the many people who love them. But that's not all; because prostate cancer shares genetic similarities and will share treatments with at least 16 other cancers—including breast, ovarian, lung, and colon—the funds we raise will save millions more lives.


**Please visit [manycancer.org](http://manycancer.org) today and join the movement.**

*It takes more than one person to end prostate cancer.*  
**It takes *many.***

# TREATING THE GENE: A Survivor Story

“In the last six months, I’ve gone from shockingly, disastrously ill to feeling great. I’m still cautious; nobody knows how long this is going to work. There’s no data on people like me.”

— Mark Meerschaert



Mark Meerschaert (far-right) with wife Carmen Meerschaert, MD (Internal Medicine), daughter-in-law Michelle Yang, son Bob Zammit, three-year-old grandson Kai Zammit, and dog Phoenix.

In a matter of weeks, Mark Meerschaert went from being an athlete to someone who could barely walk. Metastatic prostate cancer had come from nowhere and spread like wildfire throughout his body.

A highly respected mathematics professor and researcher—the kind who fills up the blackboard in his classroom with labyrinthine calculations to answer questions of probability, statistics, physics, and the like—he did what he does best: looked at the numbers. Men with widespread prostate cancer that is not responding very well to standard-of-care treatment don't live very long.

So then Mark did what we at PCF believe all men should do: He became his own advocate, did some research, and found a different doctor, Heather Cheng, MD, PhD, a medical oncologist at the Seattle Cancer Care Alliance at the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center. Dr. Cheng started the world's first prostate cancer genetics clinic.

It turns out that Mark has a bad gene that runs in his family, called BRCA2. When it is mutated and not working as it should, BRCA2 is notorious for increasing the risk of breast and ovarian cancer. But recently, scientists discovered that it also increases the risk of prostate cancer.

Because of Mark's bad copy of BRCA2, Cheng immediately focused on this gene and suggested a very different type of treatment: off-label use of a drug called olaparib, currently approved by the FDA to treat ovarian cancer. Olaparib is a PARP inhibitor; it blocks a protein that cancer cells need to repair themselves, and has worked especially well in people with defects in the BRCA2 gene. Olaparib and other PARP inhibitors such as rucaparib and niraparib are currently being studied in clinical trials for prostate cancer patients.

"She said, 'Let's try something else,'" Mark recalls. Cheng told him that the medicine may take a few months to kick in fully. "I started olaparib in October of 2016. At the end of 2016, we did a bone scan, and saw that there was cancer all over the place: my ribs, hips, legs—I can't remember all the places—some lymph nodes. One day, I walked my dog, and I had to sit down," right in the middle of the walk, "and rest for 20 minutes." That fall, Mark—on the faculty in the Department of Statistics and Probability at Michigan State University in East Lansing—organized a conference. As the moderator, Mark was supposed to stand up for five minutes between talks and moderate discussions. "I couldn't stand up for five minutes."

He used a cane, then a walker, then a wheelchair. He took a leave of absence from his job. "I didn't teach. I stand at the blackboard, walk around, write things on the board, move around, talk to the students. Math is like music; it's a skill. You actually have to do it with your hands. You have to pick up a piece of chalk and write on the blackboard. I couldn't do what I do."

But now he is looking forward to returning to work. "The great thing is," starting early in 2017, "I just slowly started to feel better and better," he says. "At some point, I said, 'Maybe I can go for a walk again. I had a little numbness in my foot, but I said, 'I'm going to keep walking,' so I did. I walk my dog every day, a couple of miles. Now even the numbness is gone."

He has not had a follow-up bone scan yet. But “I know how it felt to have tumors in my spine and my hip. I couldn’t walk and I couldn’t stand, and now I can. I’m pretty sure when they do another scan what it’s going to show. In any case, I don’t care what it shows, because I feel good.

“When you’re 61 and in two or three months you go from an active life, running, walking, and riding my bike—to not being able to stand up for five minutes and your wife is pushing you through the airport in a wheelchair – I am overly enthusiastic to feel normal, because normal seems so good. Just being able to go for a walk: I always enjoyed it, now I really cherish it. Because when you take it away, you really realize how much it means to you.

“In the last six months, I’ve gone from shockingly, disastrously ill to feeling great—I’m still cautious, still waiting for the other shoe to drop; nobody knows how long this is going to work. There’s no data on people like me. But now I feel great.”



Heather Cheng, MD, PhD  
Seattle Cancer Care Alliance,  
University of Washington  
School of Medicine, and  
Fred Hutchinson Cancer  
Research Center  
*2015 Kelsey Dickson-PCF Young  
Investigator Award recipient*

## Bombshell: The Family History He Didn't Know About

Mark is one of the pioneers of gene-targeted treatment for prostate cancer—medicine that is, as Cheng explains, “tailored to the weakness of his cancer resulting from a specific gene mistake in that cancer, rather than just treating it the same as all prostate cancers.”

“I knew that I was BRCA2 positive before I was diagnosed with prostate cancer,” he says; after his brother was diagnosed with breast cancer, several members of Mark’s family got genetic testing.

But he never expected to get prostate cancer. In fact, although Mark had gotten a PSA test every year, he had stopped. “My doctor said, ‘We don’t need to do PSAs.’ The concern was that there were unnecessary biopsies and even surgeries, and they’ve actually dissuaded people from screening.” So he stopped getting the PSA test. “For two years I didn’t get a PSA.”

Mark believes the policy of not screening men because of a fear of overtreatment is misguided. “A PSA costs almost nothing. To me it’s a misreading of the statistics,” somehow saying it’s worse for some men to get unnecessary biopsies than for other men to miss their shot at an early cancer diagnosis.

In 2013, Mark developed some urinary symptoms, and went to see a urologist. “It was Black Friday, the day after Thanksgiving. When everyone else was going to the mall, I went to the hospital and got a biopsy.” Cancer was found.

Around this time, he received some bombshell news: “My dad had had prostate cancer, but I never knew that until after I was diagnosed. Had I known that, I would have kept PSA screening.” Mark’s father had other health problems, as well, and died of lung cancer. He had been treated for prostate cancer many years before when Mark was away in college, and his parents had never said a word. “I’m a big fan of sharing knowledge with your family, even though it might be a little embarrassing. You might not feel comfortable talking to your kids about things like impotence, but they really need to know.”

Mark was put on a two-year course of androgen deprivation therapy (ADT) and given 42 daily treatments of external-beam radiation therapy. “ADT is not that bad,” he says. “Radiation is not that bad. I was feeling okay. I was living my life and going to work.” Well-meaning people told Mark the same things that many men with prostate cancer hear—that “prostate cancer is one of the good ones, the progression is really slow.” The two-year course of ADT ended in March 2016.

“By July of 2016, something just felt a little off. I went to see a urologist. He said, ‘There’s some scar tissue, I don’t think it’s anything to worry about, I saw something kind of weird, so I sent it off for a biopsy.’ It came back as high-grade cancer,” Gleason grade 9. The prostate cancer had come back with a vengeance. His PSA peaked at 36.



Mark Meerschaert enjoys time with his three year old grandson, Kai.

## Genetic Tumor Sequencing

When Mark went to the Seattle Cancer Care Alliance, “they retrieved the tissue from last July and sequenced it.” This is an essential step in precision oncology, because prostate cancer can change over time. The genetic makeup of the cancer in Mark’s first prostate biopsy in 2013 was not the same as the tissue removed in 2016, after the cancer had time to mutate and become more dangerous. “They found out that I have the BRCA2 mutation in one of the two copies in my germline, but in the metastatic cancer cells, it was mutated in both copies.

“Dr. Cheng said, ‘Your cancer is very aggressive, but that might work in your favor going the other way.’” That turned out to be absolutely correct. It got bad really fast, and it got better really fast.” His PSA is now down to 7 and he is still taking the olaparib. “I guess I’ll keep taking it as long as it works.” The question is, what happens next?

“I’m very interested in things like the five-year survival rate for people like me. Nobody knows. They’ve only been using olaparib since 2015, and the studies were on ovarian cancer.”

So there are no guarantees. However, Mark says, “I can deal with that. I will be happy for what I get. I’m cautiously optimistic. The only thing prostate cancer has to do with my day-to-day life is, I take a bunch of pills, and I usually take a nap after lunch. If I’m back at work in the fall, I’ll probably take a nap after lunch.

“I do feel like this is something pretty remarkable. My God, what if this had happened five years ago?” 🍷




# ONE IN NINE ADVANCED PROSTATE CANCERS ARE CAUSED BY HERITABLE GENES

## Prostate Cancer Isn't Just About Men Anymore


Prostate cancer isn't just about men anymore. A recent study led by PCF Dream Team member Peter Nelson, MD, and PCF Young Investigator, Colin Pritchard, MD, PhD, both of the Fred Hutchinson Cancer Research Center in Seattle, WA, has shown that 12% of advanced prostate cancers may be caused by mutations in 16 different genes that can be passed down in families. This means that men's cancers and women's cancers are not exclusive – they can be caused by the same genes and run in the same families.

Breaks in DNA occur thousands of times in each cell cycle, and normal cells have about half a dozen ways to combat DNA damage. However, mutations in DNA damage repair (DDR) genes can lead to the accumulation of mutations that promote tumor formation. Most notable of these are defects in BRCA1/2 genes, which are infamous for increasing a woman's risk of breast and ovarian cancer.

The researchers are now encouraging all patients with metastatic prostate cancer, regardless of age or family history, to obtain genetic testing and counseling for inherited mutations in DNA repair genes for two reasons. First, PCF-funded research has found that patients may benefit from specific therapies, such as PARP-inhibitors like olaparib, and platinum chemotherapy, that are particularly active against tumors with DNA repair gene mutations. Second, both male and female family members of men found to have these inherited DDR mutations should seek genetic counseling and talk with their physicians to determine their own risk and recourse for prostate, breast, ovarian, pancreatic, and other cancers.



**Peter Nelson, MD**  
Fred Hutchinson Cancer Research Center  
PCF International Dream Team  
2016 V Foundation-Stewart J. Rahr Foundation-  
PCF Challenge Award recipient;  
2011, 2013, 2015 Movember Foundation-  
PCF Challenge Awards recipient



BRCA2 was the most commonly mutated DNA repair gene in these men (5.3% of patients and 44% of all identified mutations), while BRCA1 ranked as 4<sup>th</sup> most commonly mutated in the study group (0.9% of patients and 7% of all mutations). Other potentially cancer-promoting hereditary mutations in DNA repair genes identified in this study were in ATM, CHEK2, RAD51D, and PALB2. Hereditary mutations in the ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, and FAM175A genes were found at a lower rate.

Figure: Recreated with permission, courtesy Fred Hutchinson Cancer Research Center.

These PCF-funded and practice-changing findings were reported in the most widely read medical journal in the world, *The New England Journal of Medicine*.

Based on these findings, two PCF Young Investigators have since opened clinics dedicated to identifying and treating these men. Heather Cheng, MD, PhD, of the Fred Hutchinson Cancer Research Center, opened the Seattle Cancer Care Alliance Prostate Cancer Genetics Clinic, where prostate cancer patients can determine if they carry hereditary cancer risk mutations, and learn about treatment selection and resources for family members who may be at increased risk for cancer. Todd Morgan, MD, of the University of Michigan, opened the University of Michigan Prostate Cancer Risk Clinic, where men who have not been diagnosed with prostate cancer but are carriers of hereditary mutations known or suspected to cause prostate cancer, undergo an individualized prostate cancer screening plan and receive counseling and follow-up care. 🍷

# PCF-VETERANS ADMINISTRATION PRECISION ONCOLOGY PARTNERSHIP

## A Veterans Health Initiative to Support Our Heroes



### Prostate Cancer: A Critical Health Issue for Veterans

There is national consensus that the approximately 21 million men and women who served in the U.S. military deserve the very best health care available. These veterans have sacrificed so much—life and limb in some cases, health and wellness in many cases—and we, as a nation, owe it to them to provide high-quality, advanced medical care. Only the best for the best!

# VA

## U.S. Department of Veterans Affairs

The Department of Veterans Affairs (VA) is committed to developing new treatment and prevention options and, through rigorous scientific research advances, improving the quality of life for veterans diagnosed with prostate cancer. This is why the VA and the Prostate Cancer Foundation (PCF), a leading philanthropic organization that has raised more than \$700 million and provided funding to more than 2,000 research programs at more than 200 cancer centers and universities, have created a new research partnership.

Approximately 40,000 veterans are diagnosed with cancer each year. Prostate cancer is the second most common cause of cancer death, and an estimated 12,000 Veterans are diagnosed with prostate cancer annually. A number of options are available to treat prostate cancer, including medicines and surgical procedures, but some of them come with serious side effects, which can have a significant impact on a veteran's quality of life. Left untreated, prostate cancer can cause death.

During the next five years, this PCF and VA partnership will expand research into prostate cancer treatment options. The partnership will increase the number of clinical trials conducted at Veterans Health Administration hospitals, and will encourage veterans to participate in these studies so they can help bring new treatment options to millions of men with prostate cancer around the world.

Precision medicine is the cornerstone of this unique partnership. Precision medicine uses a person's unique DNA to identify the best treatment option for that individual. In recent years, doctors across the country have used precision medicine techniques to select treatments for lung cancer patients. Precision medicine has the potential to bring more individualized, targeted treatments to cancer care.

The goal of the PCF-VA agreement is to bring precision medicine to prostate cancer patients, too. We believe the research community is closing in on new treatments, and more targeted therapies will ease the burden of prostate cancer for many patients.

The PCF-VA agreement is an example of a public-private sector partnership, which has the potential to improve health care for veterans by providing access to impactful clinical trials and critical advances in genomics and molecular medicine.

This partnership is modeled after similar, successful programs that expand veterans' access to a variety of goods and services. This initiative holds great promise in advancing our knowledge about prostate cancer, and, ideally, will result in new treatment options for patients. In short, the PCF-VA program has the potential to be one of the most efficient and effective ways to fulfill our commitment to our veterans, who deserve the best we can offer. 🇺🇸

## PCF-VA LAUNCHPAD SUMMIT

November 29, 2016



On November 29, 2016, PCF President and CEO, Jonathan W. Simons, MD together with the Honorable David J. Shulkin, MD, Secretary of the Department of Veterans Affairs, signed a Memorandum of Understanding (MOU) to facilitate PCF's partnership with VA. Joining them, from left to right: Dr. Andrew von Eshenbach, the Honorable Matthew S. Collier, Dr. Poonam L. Alaiigh, Mike Milken, John Weston, R. Christian Evensen, and Rebecca Levine.



Dr. Michael Kelley, National Director of Oncology, Dept. of Veterans Affairs (center), moderates a panel on cancer care among Veterans with (left to right): Dr. Jeff Hersh, Chief Medical Officer, GE Healthcare; Dr. Jan Kimpen, Chief Medical Officer, Philips; Dr. Jason Dominitz, National Director of Gastroenterology, Department of Veterans Affairs; Dr. Jonathan Simons, President and CEO, Prostate Cancer Foundation; Dr. Bruce Johnson, President-elect, American Society of Clinical Oncology.



Dr. Bruce Montgomery, Medical Oncologist, Department of Veterans Affairs, VA Puget Sound and Co-leader of the VA-PCF POPCAP Program discusses germline testing of veterans with advanced prostate cancer and exceptional responders at the 2016 LAUNCHPAD Summit.



Jennifer Lee, MD, deputy under-secretary for Health for Policy and Services, Department of Veterans Affairs discusses innovations in cancer diagnosis and treatment at the 2016 LAUNCHPAD Summit.

# MOVEMBER FOUNDATION



Since 2007, the Movember Foundation has generously donated more than \$50 million to support 39 team science awards in the U.S., Canada, and Great Britain. As we embark upon the 10<sup>th</sup> year of our profound relationship, we are honored to continue our journey as partners as we strive to end prostate cancer deaths with precision oncology. Over the years, the Movember Foundation has emerged as an iconic symbol of advancing men's health issues on a global scale. Our partnership has improved and changed the care of every patient with advanced prostate cancer. The strengths of the Movember Foundation and PCF, with our collective global reach, provide a unique ability to raise both funding and awareness for prostate cancer while also identifying the brightest research minds in the world.

*“The Movember Foundation’s partnership with PCF is pivotal to the fulfillment of our mission to save lives.”*

— Jonathan W. Simons, MD  
President & CEO, Prostate Cancer Foundation

Many newly improved oncology decisions for increasing quantity and quality of life are a direct consequence of the Movember Foundation’s support for PCF driven research.

Thanks to Movember funding:

- 7 completely new precision drugs have advanced to testing in patients with advanced prostate cancer;
- The identification of “DDR inheritance genes” allows precise genetic counseling for the sons and daughters of 1 in 10 men with prostate cancer;
- New drugs that co-target both breast and prostate cancer along with a drug that targets ROR-gamma entered the R&D pipeline;
- Prostate cancer recurrences are being discovered sooner in PET scans;
- New prostate cancer destroying T-cells were developed in men with hormone and chemotherapy resistant disease.

**PCF is forever grateful for this valued partnership.**



Movember Foundation co-founder and Chief Mo Bro, Adam Garone with PCF CEO, Dr. Jonathan Simons at PCF’s 2016 Scientific Retreat in Carlsbad, CA.

Photography: Paul Bliese

# 2016 FUNDRAISING EVENTS



PCF had an exceptional year for events. The Charles Evans PCF Pro-Am Tennis Tour consists of four tournaments in Indian Wells, CA; Greenwich, CT; The Hamptons, NY; and Palm Beach, FL. These popular events are scheduled during peak tennis season in each city. They provide an exciting and unique experience for amateur tennis players and are the ideal way to foster new relationships with PCF. They have become a successful platform for connecting with new audiences in these communities to help raise awareness and funds that provide vital support for our most innovative life-extending research programs. **In 2016, the tour raised nearly \$2.5 million and more than \$1 million in Young Investigator commitments. The tennis program has raised \$26 million over its 18-year history.**



Above: Participants and champions at PCF's Charles Evans Pro-Am Tennis Tour events that took place in various U.S. cities in 2016.

In August, PCF celebrated the 12<sup>th</sup> year of the Charles Evans PCF Pro-Am Tennis Tournament in the Hamptons with our highly anticipated gala at the Parrish Art Museum. The evening featured special musical performances by Grammy award-winning singer Dianne Reeves, double platinum recording artist Billy Idol, the nationally recognized pop vocal group The Company Men, as well as a special performance by Francis Collins, Director of National Institutes of Health. The event raised nearly **\$3 million** in support of the foundation's work, with 100% of the funds raised throughout the weekend supporting groundbreaking discoveries in cancer research.



PCF CEO, Dr. Jonathan Simons speaks at PCF's "Come Fly With Me" fundraising dinner event, during the Breakers Tennis Weekend in Palm Beach, FL.



Singer Billy Idol performs at PCF's Hamptons Weekend tennis and fundraising event in Water Mill, NY.



Modell's Sporting Goods founder and owner Mitch Modell presents a check to PCF chairman Mike Milken for funds raised for PCF through the Modell's in-store campaign.



Guests (from left) Carmelo Anthony, John Salley, and Ray Lewis attend the 2016 Cigar Aficionado "A Night to Remember" dinner, benefitting PCF and hosted by Cigar Aficionado publisher Marvin Shanken (front).



Long-time PCF donor-supporters attended PCF's 2016 New York Dinner. From left: Ted Virtue, Debra Black, Dani Virtue, and Leon Black.



Entertainers Bernadette Peters and Matthew Morrison performed at PCF's 2016 New York Dinner at DANIEL.

2016 ended with a celebratory dinner at the legendary restaurant DANIEL, with a specially prepared menu by Daniel Boulud on December 7<sup>th</sup>. Limited to 125 people, the dinner is a highly anticipated event that provides a more intimate setting to expand current relationships and to build new ones. Guests were entertained by the multi-talented Matthew Morrison, of *Glee* fame, and the evening closed with a special performance by the critically acclaimed, two-time Tony winner, Bernadette Peters. The evening brought in **more than \$1.8 million** in ticket sales and **more than \$1 million** in support of team science awards.

# MLB & PCF Make History Together

For the *first time ever*, MLB clubs celebrated Father's Day in



In 2016, Major League Baseball (MLB) and the Prostate Cancer Foundation (PCF) celebrated their 21<sup>st</sup> season working together to cure prostate cancer—a partnership that has raised more than \$47 million for prostate cancer research through the MLB-PCF Home Run Challenge. Over the past 21 years, this program has helped reduce the U.S. prostate cancer death rate by more than 50%.



For more than 20 years, Major League Baseball has been proud to support the Prostate Cancer Foundation in the fight against cancer. We look forward to our continued work to support PCF's mission of 'curing together.'

— Melanie LeGrande  
VP of Social Responsibility,  
Major League Baseball



The Minnesota Twins love to participate each year in the Home Run Challenge because we know that our donations support the highest quality research that will change the landscape of treatment for cancer patients."

— Bryan Donaldson  
Senior Director, Community Relations  
Minnesota Twins Baseball Club



# in the 2016 Home Run Challenge!

specialty-designed uniforms to raise awareness for prostate cancer.



For the first time, on Father's Day 2016, every MLB team wore specialty-designed blue-accented uniforms in support of the Home Run Challenge and Prostate Cancer Foundation. MLB sluggers hit 241 home runs in 2016, raising more than \$2.3 million from pledges and donations made by 2,140 donors—an all-time record!



“It was our pleasure to support the Home Run Challenge because PCF uses the funds with relentless efficiency to support the top cancer researchers around the world and monitor their progress to ensure that our philanthropic investment is used wisely.”

— John Stanton  
Owner, Seattle Mariners



“The Milwaukee Brewers support the Home Run Challenge because our team's contribution goes to prostate cancer research projects that deliver the greatest impact for patients. We know we're making a difference.”

— Mark Attanasio  
Owner, Milwaukee Brewers

# A SURVIVOR'S APPEAL FOR SUPPORT



PCF Board member and prostate cancer survivor, Andy Astrachan

## “There are so many of us.”

Today I am healthy, fit, active, and enjoying life very much. But I'm always thinking about my PSA. It is very low. It has always been very low, but the number can be deceptive; it may have nothing at all to do with the actual grade, the seriousness and aggressiveness, of my cancer. And it won't go away. I am here today because I had access to excellent information. I have had surgery, radiation therapy, Provenge®, the prostate cancer vaccine, more surgery to remove cancer in a lymph node, more radiation, and a short course of ADT.

I joined the Board of the Prostate Cancer Foundation because I want to help find the cure for this disease. And I want to talk to you briefly about how I have helped change the PCF's mission with the new movement, Many vs Cancer. Until recently, the PCF communicated mainly with scientists. Our mission was highly focused: to fast-track the research that will find a cure for prostate cancer, to support investigators so they can do the science that otherwise wouldn't get funded, and to save the lives of men who have prostate cancer that currently can't be cured.

## Many vs Cancer

The idea to democratize the dissemination of information and mobilize the prostate cancer community really began with the realization that I have access to so much information that most people don't have. The only thing standing in the way of other people having that information is using technology. Many vs Cancer (MvC) represents a major shift in the Prostate Cancer Foundation, to communicate directly to patients, through PCF.org and MvC, and it really is a result of my observation that most information on the web is useless for patients.

Many cancer information websites are sponsored by companies that make cancer drugs, specific surgical equipment, or otherwise have something to sell. Worse, much of what they have to say is just not particularly useful. So I went to the PCF Board and said, “We have all the information. We should be communicating that to patients.”

For more than 20 years, the ethos at the PCF was that we're a research organization; we talk to researchers and scientists. That's how the disease is going to get cured. We talked in a language that was understandable to scientists and communicated directly to them, and if patients came on the website and got help, great. The thought was, we're going to help them all by funding the cures and making advancements in the disease.

I believe the people who have the biggest vested interest in funding the research and having it succeed can easily fund it—not in giant grants, but in small gifts from the heart, through the mighty power of sheer numbers. All of us—prostate cancer patients and their loved ones, caregivers, friends, and those who want to see them survive—together can crowd-fund a billion dollars.

The cure is not going to come from the federal government. Nobody else is going to do it. There's great power in our numbers. Huge power in our numbers.

Every contribution counts; none is too small and of course, none is too large. Will you be part of the cure, too?

Andy Astrachan

# SUPPORTING CURES

There are millions of men currently living with prostate cancer. To support the urgent need for better treatments and cures, the Prostate Cancer Foundation offers individuals and charitable foundations various options for becoming involved and supporting crucial research.

## Donations

Please mail your check to:

Prostate Cancer Foundation  
1250 Fourth Street  
Santa Monica, CA 90401

To make an online contribution, please visit our website  
[www.pcf.org](http://www.pcf.org)

## Blue Ribbon Society

- Join our elite group of recurring donors with an automatic monthly payment using a credit card, debit card or bank account.

## Memorial or Tribute Gifts

- Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others with a tribute gift.
- If desired, PCF can also set up a special webpage to honor your loved one and collect donations.

## Matching Gifts


- If your company offers an Employee Matching Gifts program, you can make your hard-earned dollars go twice as far with a matching gift to PCF.

## Other Gift Suggestions

- Gifts of stock.
- Remember PCF in your will.
- Name PCF as a beneficiary of your IRA or life insurance policy.
- Federal employees and retirees participating in the Combined Federal Campaign (CFC) can designate PCF as a beneficiary.

For more information, visit:

[www.pcf.org/donate](http://www.pcf.org/donate)



## PCF Research Awards

PCF is currently focusing on 3 research priorities:

1. Precision Immunotherapy
2. Precision Medicine
3. New Precision Drug Discovery

PCF advances its research priorities through 3 competitive award types:

### Challenge Awards

(\$1,000,000 and above for 2- to 4-year programs)

Challenge Awards make large investments in multi-year team science projects that have a high potential for delivering new treatments.

### Creativity Awards

(\$300,000 for 2-year programs)

Creativity Awards support the development of high-risk, high-reward ideas from established senior scientists.

### Young Investigator Awards

(\$225,000 for 3-year career investment)

The Young Investigator Awards offer early-career and project support for exceptional investigators (generally 35 years old and younger) and their ideas, who are committing their lives to the field of prostate cancer. Their institutions match the award dollar-for-dollar.

# 2016 DONOR ROLL

The support of our generous donors makes all that we do at PCF possible. This honor roll acknowledges actual gifts of \$1,000 or more, exclusive of pledges, made to PCF during calendar year 2016. We thank you, our friends and supporters, for your continued commitment to PCF's mission.

## \$5,000,000+

Movember Foundation

## \$1,000,000-\$4,999,999

Anonymous

David and Judith Fleischer  
The Stewart J. Rahr Foundation  
The Stupski Foundation

## \$500,000-\$999,999

Anonymous

Janssen Research and  
Development, LLC  
Kern Family Fund  
David H. and Julia Koch  
Milken Family Foundation

## \$250,000-\$499,999

Anonymous

Astellas Pharma Global  
Development, Inc.  
Rush Limbaugh  
Mr. Brent R. Nicklas  
Russell H. Norberg Trust  
Roche Translational & Clinical  
Research Center [HOWARD]  
The San Francisco Foundation  
Sanofi-Aventis

## \$150,000-\$249,999

Dr. Elliot Abramowitz  
ASICS America Corporation  
Mrs. Maria Bartiromo and  
Mr. Jonathan Steinberg  
Bayer HealthCare  
Pharmaceuticals, Inc.  
Mr. David S. Blitzer and  
Mrs. Allison Blitzer  
Neil and Sandra DeFeo  
Family Foundation  
The Durden Foundation, Inc.  
Mrs. Earl Durden  
Mr. Michael Durden  
Peter and Laurie Grauer  
Clay and Lynn Hamlin  
The Katz Family Foundation –  
Drew Katz  
Richard S. and Karen LeFrak  
Charitable Foundation  
Major League Baseball Charities, Inc.  
Howard and Nancy Marks  
Merkin Family Foundation, founded  
by Richard Merkin, MD  
Paulson Family Foundation

Mr. Arthur Rabin and  
Mrs. Selma Rabin  
The Steele Foundation  
Mr. Eustace Wolfington

## \$100,000-\$149,999

Anonymous [2]  
Joseph and Annette Allen  
Andrew J. Astrachan /  
AJA Charitable Fund  
Susan and Jim Blair  
The Bill and Ann Bresnan  
Foundation, Inc.  
Steven A. Burd  
Dendreon Pharmaceuticals  
Edward P. Evans Foundation  
Mr. and Mrs. Michael Gelband  
Thomas H. Lee and Ann Tenenbaum  
Dalia & Larry Leeds / The Leeds  
Family Foundation  
The Honorable Earle I. and Carol Mack  
Shmuel Meitar  
Minnesota Twins  
Modell's Inc.  
David P. Nolan Foundation  
Lewis S. Ranieri  
Brian and Patricia Reynolds  
Stephen M. Ross  
Mr. Nicholas S. Schorsch  
Stephen A. Schwarzman  
Beth Koblner Shaw and  
David E. Shaw  
Estate of Robert Charles Silhavy  
Julie and Bobby Taubman  
Ted and Dani Virtue  
Zisk Family Foundation

## \$50,000-\$99,999

Anonymous [2]  
Arangold Corporation  
Mark and Debbie Attanasio  
Aven Foundation /  
Mr. John W. Stanton  
Ron and Judy Baron  
Reina and Emilio Bassini  
Dr. Michael M. Berns and  
Mrs. Tricia Berns  
Mr. and Mrs. Seth Bernstein  
Todd Boehly  
Mr. Alan W. Breed  
Arthur and Eva Byrnes  
Ray and Patti Chambers  
Clovis Oncology, Inc.  
James H. Coleman

Bethany and Niko Elmaleh  
Ralph and Cynthia Finerman  
Genomic Health, Inc.  
John R. and Kiendl Dauphinot  
Gordon Fund  
Joshua J. and Marjorie Harris  
Kenneth and Janet Himmel  
William P. and Dorian S. Jordan /  
William P. and Dorian S. Jordan  
Foundation, Inc.  
Kissick Family Foundation  
Mr. and Mrs. Steven B. Klinsky  
Kovler Family Foundation  
Mr. Gerry Lenfest  
Mr. James H. Litinsky  
The Maguire Foundation  
Mr. and Mrs. Donald B. Marron  
Medical Research Charities  
R.N. Milikowsky Family Foundation  
Mr. Anthony D. Minella and  
Mrs. Sage Minella  
MJR Foundation  
Mr. Thomas S. Murphy, Jr.  
Mr. Christian L. Oberbeck  
Progenics Pharmaceuticals, Inc.  
The Republic of Tea  
The Rodin Family Trust  
Sheila and Daniel Rosenblum  
Daryl and Steven Roth  
Marc J. and Carolyn Rowan  
The Mara and Ricky  
Sandler Foundation  
Mr. Ilan Shalit  
Mark and Rosalind Shenkman  
Mr. Brian Sheth  
Shostak Charitable Trust  
Barry and Ilene Silverman  
David E. and Jacqueline S. Simon  
Charitable Foundation  
Mr. Marc D. Taub  
The Thompson Family Foundation  
Vittoria Purdy & Cavallaro, LLP  
Chuck Wagner  
Elaine Wynn  
Mr. and Mrs. David Yurman  
Mr. and Mrs. Eric Zinterhofer

## \$25,000-\$49,999

Anonymous [2]  
The Cecile and Fred  
Bartman Foundation  
Mr. Herb Biggers  
Lucy and Henry Billingsley Fund at  
Dallas Women's Foundation

Boston Red Sox Foundation  
Anthony and Jamie Carr  
Dick and Lisa Cashin  
Chicago White Sox  
Clean Energy  
Jerry and Adrienne Cohen  
Mr. Jim Cohen  
Mr. and Mrs. Steven A. Cohen  
Robert D. Collins Fund  
Mr. Michael DeAddio  
Divcore Real Estate Asset  
Management, LLC  
R. Christian B. Evensen  
Eugene and Sallyann Fama  
Mr. Jeffrey W. Feldman  
Mr. Kenneth Fishel  
Mr. James H. Fordyce  
Brian P. Friedman Family Foundation  
Sam Herzberg  
Hologic Gen-Probe  
Elizabeth and William Kahane  
Jerry Katell, Katell Productions, LLC  
Mr. William Rance King  
Mr. Arik Kislin  
Estate of Dennis A. Klein  
Kojaian Properties, Inc.  
Stephanie and Ron Kramer  
Lands' End  
Mr. Fred B. Luddy  
John & Linda MacDonald Foundation  
Jerome Meislin  
The Moreno Family Foundation  
George and Sandra Norcross  
Mr. and Mrs. Henry L. Nordhoff  
Mr. T. Boone Pickens  
Mr. Patrick Racz  
Mr. Robert Rosenkranz and  
Dr. Alexandra Munroe  
Jason Safriet  
Saratoga Management Company, LLC  
Sempermed USA, Inc.  
Marvin and Hazel Shanken -  
M. Shanken Communications, Inc.  
Mr. Mickey Shapiro  
Jennifer and Seth Stier  
Roger and Susan Stone  
Mr. Vincent Viola  
Estate of Charles P. Troxel

## \$15,000-\$24,999

Anonymous [2]  
Mr. and Mrs. William A. Ackman  
The Elias, Genevieve and Georgina  
Atol Charitable Trust

Bavarian Nordic  
Candice Beaumont  
Jay and Alison Bernstein  
Mr. Edwin Charles Bessant  
Mr. Todd L. Blue  
Mr. Michael Cellucci  
Mr. David Cipriano  
Mr. Jim Clerkin  
Howard Cox  
Mr. and Mrs. William Curry  
Mark and Sally Ein Foundation  
Exosome Diagnostics, Inc.  
Mr. Steven J. Feilmeier and  
Mrs. Regine S. Feilmeier  
Mr. Joseph Flanagan  
Mr. Glenn Fuhrman  
Genentech, Inc.  
General Cigar Co.  
GenomeDx Biosciences, Inc.  
Mr. Jeff Greene and Mrs.  
Mei Sze Greene  
Mr. Paul Huston  
Michelle and Joseph Jacobs  
Mr. Bruce A. Karsh  
Ms. Lindsay D. Kronengold  
Alice Lawrence Foundation, Inc.  
Leeolou Charitable Fund  
Robert Levin / Ashton Distributors  
Dean and Marianne Metropoulos  
Mr. Edward L. Milstein  
Moët Hennessy USA  
Charitable Foundation  
My Father Cigars, Inc.  
Miles Nadal  
Mr. and Mrs. Jorge L. Padron  
Dean E. Palin  
Mr. Rocky Patel  
David Pecker  
Sandra and Lawrence Post  
Family Foundation  
Mr. David A. Sachs and  
Mrs. Karen Richards Sachs  
Mr. and Mrs. David A. Salzman  
Mr. Kern W. Schumacher  
Mark J. Simon  
Mr. Eric Sugrue  
Mr. Robert L. Thornton, Jr.  
The Robert & Jane Toll Foundation  
USA Volleyball  
The Wagner Family Foundation /  
GoldenTree Asset Management  
Mr. and Mrs. Daniel Weingeist  
Gregory and Mindy White  
Mr. Andrew Whittaker and  
Mrs. Stephani Whittaker  
Douglas Wood

#### **\$10,000-\$14,999**

Anonymous [2]  
Robert W. and Deanna Adler  
AmeriHealth Caritas Services, LLC  
Mr. M. Scott Atkison and  
Mrs. Paula L. Atkison  
Ballard Spahr LLP

Mr. and Mrs. David C. Brown, Jr.  
Cincinnati Reds / Mr. Robert Castellini  
Commonwealth-Altadis, Inc.  
Mr. and Mrs. Eric K. Davidson  
Drew Foundation  
Dur-A-Flex Foundation  
R.S. Evans Foundation  
Jack Farrell  
Mr. Edward Garden and  
Mrs. Brooke Garden  
Anne K. Gilhuly  
Michael and Linda Gold  
Bennett and Meg Goodman  
Grandstand Sports & Memorabilia  
The Daniel B. and Florence E.  
Green Foundation  
Mr. Lawrence H. Hayward and  
Mrs. Sheree Hayward  
Mr. and Mrs. Thomas F. Herche  
Lane and Clark Howard,  
Clark Howard, Inc.  
Mr. Jeff M. Johnson  
Mr. Philip Korb  
Mr. Michael Lehrman and  
Mrs. Marcy Lehrman  
Mr. and Mrs. Eric Luse  
Mackintosh Charitable Trust /  
Mrs. William Mackintosh  
Survivor Trust Of The Meyer Trust  
Mr. Kammy Moalemzadeh  
Mr. Terry R. Montesi and  
Mrs. Allison Montesi  
Mr. Donald R. Mullen, Jr.  
Mr. Jonathan E. Newhouse  
Philadelphia 76ers  
Polo Ralph Lauren Foundation  
Mr. Douglas Rachlin  
Cliff and Debbie Robbins and the  
Robbins Family Foundation  
Ellen and Richard V. Sandler /  
Richard and Ellen Sandler  
Family Foundation  
Richard and Phyllis Sharlin  
Howard Shore  
Mr. Suhail A. Sikhhtian  
Herbert Simon Family Fund  
Mr. Shawn N. Skelton and  
Mrs. Letal Skelton  
Mr. Steven Tananbaum and  
Mrs. Lisa Tananbaum  
Tarnopol Family Foundation, Inc.  
Ms. Tanya Tyburski  
Mr. and Mrs. Michael W. Urbut  
The Weintraub Family Foundation  
Mr. and Mrs. Harry J. Wild  
Mr. Jacob H. Zamansky  
Mr. Mark Zucker

#### **\$5,000-\$9,999**

Anonymous [5]  
Mr. Frank C. Alexander, Jr.  
ARD Red Lion, LP  
Mr. James D. Bagwell  
Mr. Keith Bertolino  
Mr. Andrew F. Brooks

Ms. Aviva Carmy and  
Mr. Harry Horowitz  
Mrs. Linda Chambers  
Gary Charlesworth  
Allen and Jill Chozen  
Kelly Chung and Kerry Hagen  
Clayman Family Foundation  
Mr. Lewis Clayton  
Mrs. Robin Cohen  
Connecting Capital & Partners, LLC  
David and Courtney Corleto  
Mr. J. Michael Crouch  
Ms. Ramola Daswani  
Stephen Edelmann, Edelmann  
Family Foundation  
David and Marsha Ederer  
Mr. Daniel M. Elperin  
FragranceNet  
Mr. Alan Franco  
General Motors Retirees Association  
Mr. Mark Gerson and  
Mrs. Erica Gerson  
Mr. John Grace and Mrs. Diane Grace  
George & Reva Graziadio Foundation  
Douglas J. Hertz Family Foundation  
Mrs. Caroline Hofland  
Mr. George B. Huber  
Karma Automotive, LLC  
Mr. and Mrs. David H. Kelsey  
Kathleen and Kirk Knous  
Stacey and Larry Kohl  
Lowell D Kraff & Marc Byron -  
Trivergance LLC  
Mr. Carey F. Lathrop  
Mr. and Mrs. Sam Logovinsky  
Mr. Edmund Lomasney  
Mr. and Mrs. Paul Madura  
Mr. William McDaniel  
Mr. Bill McKernan  
Mr. and Mrs. George A. Mealey  
Mr. and Mrs. Michael P. Muldowney  
Mark and Linda Newman, the LM  
Newman Family Foundation  
NSM Insurance Group  
Mr. Martin Nussbaum and  
Mrs. Kane Nussbaum  
Ms. Rama Patel  
Pernod Ricard USA  
Mr. Stephen Pomeroy  
Richard B. Ravel & Susan M. Anderson  
Ms. Kay Redmond  
Relay Network, LLC  
Mr. Brian Riley  
Mr. Arnold Rosenshein, III  
Mr. Dov Scharfstein  
Mr. William Schwartz  
Mr. Brian Selmo and  
Mrs. Suzanne Selmo  
Stephen and Suzy Shechtman  
Mr. Laurence Sherman  
Mr. Eric Sinoway  
The Sire Foundation  
Liz and Mike Slive  
The Sloan Foundation  
Mr. Jacob A. Spain

Ms. Anne T. Spangenberg  
Mr. Carl Sperber  
Gary Stoneburner  
Mr. James A. Thompson  
Mr. and Mrs. Richard Todd  
Jesse I. Treu  
The Tweten Charitable Foundation  
Elizabeth Ventura and  
Stephen Eisenmann  
Dr. and Mrs. Andrew C.  
von Eschenbach  
Ms. Caroline A. Walker  
Mr. James Wiant  
Mrs. Beth Widstrom-Anderson  
Art Winkleblack

#### **\$2,500-\$4,999**

AmeriGas Propane  
The Beneficial Foundation  
Mr. James Berg  
Blank Rome, LLP  
Mr. Jose Blanco and  
Mrs. Emma Viktorsson  
Mr. Dwayne Bobbitt  
The Boucher Charitable Foundation  
Boutique Blends Cigars LLC  
Bravelets LLC  
Beth C. Burdick  
Ms. Kristi Burlingame  
The Capital Group Companies  
Charitable Foundation  
Mr. Paul Chapman  
Ms. Erin Clemens  
Mr. and Mrs. Michael S. Day  
Mr. Bruce Dereschuk  
Mr. Philip F. DeSantis  
Andrew H. Feinman  
Mr. Ilya Feldman  
Dr. and Mrs. John F. Ferguson, MD  
Mr. Abel Fernandez  
First National Bank in Sioux Falls  
Mr. Abraham Flores  
Ms. Cynthia Fuente  
Philip H. Geier, Jr.  
The Gibson Family Foundation  
Mr. and Mrs. Wayne Giebler  
Litto Gomez  
Granite Construction Inc.  
Mr. and Mrs. Richard Granville  
Green Charitable Fund  
Mr. Harley Greenfield  
Robert Grossman  
Thomas R. Hagadone and  
Pamela J. Miller  
Healthcare Initiatives, Inc.  
Andrew L. Heiskell  
HomeStreet Bank  
Mr. Tim G. Jaeger  
Kenneth T. Johnson Trust  
Kansas City Royals  
Klin Tobacco, LLC  
Mr. and Mrs. Joseph M. La Motta  
Mr. Tor Langoy

Dr. Robert Levine and  
Mrs. Michele Wornow Levine  
The Thalia & George Liberatos  
Foundation  
Lyonross Capital Management LLC  
Richard F. Mackey  
Stewart Manheim  
Mr. Tom Maresh and  
Mrs. Carolyn Maresh  
Stanley and Pamela Maron  
Mr. Andrew McElaney  
Mr. and Mrs. Robert P. McNutt  
Ms. Mary Moore  
Mr. Eric Newman  
Nicholas Industries, Inc.  
Mr. Drew Nieporent  
Jonathan R. Novak  
Daniel Offutt III Private  
Foundation Trust  
Mr. Gilberto Oliva  
Mr. Robert A. Olstein  
Mrs. Janice Orozco  
John Paffenbarger  
Mr. William C. Paley  
Charles Maxfield Parrish and  
Gloria F. Parrish Foundation  
Mr. Donald W. Phillips  
William L. Price  
Progenics Pharmaceuticals, Inc.  
Mr. Jonathan Ressler  
James S. Riepe Family Foundation  
Mr. and Mrs. Richard A. Rigg  
Michael and Debbi Fields Rose  
Mr. Robert Rosenbaum  
Mr. and Mrs. Jay K. Rosenblatt  
Edward B. Rust, Jr.  
Mr. and Mrs. Gerard M. Ruvo  
Mr. David Schreiner  
Estate of Dennis Shea  
Mr. Gary Singer  
Starkey Sports Consulting, LLC  
Toby Strogatz and Stephen Klein  
Mr. James A. Stroud  
David V.N. Taylor Foundation  
Mr. Mark Teasdale  
Timothy G Davis, Inc.  
Mr. E. Paul Tinsley  
Mr. Donald J. Toumey  
Ms. Wendy Ull  
Mr. Julian P. Van Winkle  
Mr. David Viniar and Mrs. Susan Viniar  
Mr. and Mrs. Douglas O. Waikart  
Ms. Deni Warren  
Will K. Weinstein  
Martin Wice  
Mr. G. Winterhalter and  
Mrs. J. Winterhalter  
Mr. John M. Zemke and  
Mrs. Ann Zemke

**\$1,000-\$2,499**

Anonymous [20]  
111th Precinct Youth Council  
Mr. Derek Abel

Alden and Elizabeth (Bette) Abraham  
Charitable Gift Fund  
Accurray Incorporated  
Mr. Brian Adams and  
Mrs. Monica Adams  
Mr. Chris Adams  
Mr. Stanley M. Adler  
Advanced Technology Group  
Mr. and Mrs. Dale Allen  
Alpha Chi Alpha  
Mr. William H. Alspaugh  
Mr. and Mrs. Ellsworth C. Alvord, III  
AmazonSmile Foundation  
Mr. Martin Anaya  
Mr. John R. Anderson  
Mrs. Nina Anderson  
Mr. and Mrs. Philip R. Anderson  
Sarah and Marquard Anderson  
Mr. and Mrs. Nicholas V. Angelucci, Jr.  
Mr. Carmelo K. Anthony  
Mr. and Mrs. Alan Appelbaum  
Aramark Global Business Services  
Frank J. Arcella  
Matthew Arcella  
Mr. Charles Armstrong  
Ms. Jen Artis  
AT&T Services, Inc.  
Mr. Ryan Atkinson  
Mr. Eric Aust  
Ms. Barbara Austell  
J. Kent and Dana S. Bailey  
Mr. John Balourdos  
Jeffrey and Pamela Balton  
Paul Baranay  
Norma and Paul Barash  
Mr. Stephen Barnette  
Mr. Christopher E. Barry and  
Mrs. Carol Barry  
Mr. Michael J. Batza, Jr.  
Mr. Thomas E. Beach  
Fred Bedard  
Elliott H. Berger  
Mr. and Mrs. Barry M. Berish  
Cantor and Mrs. Alexander Berkovich  
Suzanne & Saul Berkowitz  
Mr. and Mrs. Barry Berlin  
Mr. Michael Bernstein and  
Mrs. Sara Bernstein  
Douglas Berry  
Mr. and Mrs. Fred B. Bialek  
Mr. Geo Blackshire  
Mr. Lawrence Blanford  
Mr. Richard Bogomolny and  
Ms. Patricia Kozerefski  
Mr. and Mrs. Richard Boland  
Salvatore and Alison Bommarito  
Mr. David Bonn and Mrs. Lorene Bonn  
Ms. Stephanie P. Bourassa  
Mr. Stephen S. Bowen  
Mr. Peter Bower  
Mr. and Mrs. Todd J. Brading  
Braman & Associates, Inc.  
Mr. Michael Bray and  
Mrs. Barbara Bray

Mr. Emil J. Britt, Jr.  
Mr. J. Bryant Brooks and  
Mrs. Margaret M. Brooks  
Gina K. Brouman-Sacks,  
Leslie Sacks Gallery  
David P. and Jerilyn Brownell  
Mr. Charles K. Brumit  
Mr. Lawrence R. Bulduc and  
Mrs. Shirley A. Bulduc  
Byron's Liquor Warehouse  
Mr. Joseph Cabral  
Ms. Amy Jane Cadieux  
Craig and Caryn Caffarelli  
Mr. John Capuano  
Mr. Lon Carlson  
Harvey L. Carter, III, MD  
Mr. Evan Cascio  
David and Suzanne Chonette  
Mr. and Mrs. James T. Clarke  
John H. Cluster  
Mr. Don Clinkinbeard  
Mrs. Catherine Codd-Palmer  
Ms. Christine Cole  
William S. Comanor, PhD  
Raoul S. Concepcion, MD  
Estate of Donald L. Connors  
Mr. Kevin J. Conway and  
Mrs. Dee Conway  
Mr. Sean Coogan  
Mr. Matthew Cooper  
The Corning Palace Theatre  
The Stephen W. Craig  
Family Foundation  
Ms. Aida M. Croal  
Edgar and Elissa Cullman  
Mr. Joseph L. D'Amico  
Mr. Donald Dammann  
Mr. James A. Davidson  
Mr. David A. Dechman  
Ms. Deanna Deel  
The Distinguished Programs  
Group, LLC  
Mr. and Mrs. E. James Dixon  
Mr. and Mrs. Joseph D. Doyle  
Dr. and Mrs. James T. Drace  
Mr. and Mrs. William E. Dreyer  
Michael Dunitz Crisis Foundation  
Mr. and Mrs. Robert J. Dunne III  
E & J Gallo Winery  
Mr. and Mrs. James W. Eggenberger  
Mr. Christian Eiroa  
Mr. Jack P. Ellman  
Embrace Healthcare, LLC  
Mr. Mark D. Emmerson  
Mr. Dennis Esposito  
Mr. Michael P. Esposito and  
Mrs. Wendy E. Esposito  
Evans Insulation Company  
Mr. and Mrs. Edward R. Evans  
Mr. Andrew R. Fabricant  
Mr. and Mrs. Steven J. Farella  
Mr. & Mrs. Michael Farrell  
Ms. Connie Faucheux  
Mariiita and George Feldenkreis  
Ken and Caryl Field

Mr. John F. Finch  
Gordon E. Finley, PhD  
Mr. Jerome Fiore and Mrs. Terri Curtis  
Ms. Sandra Fitzgerald  
Mr. Theodore Floor  
Mr. Ricardo Flores  
Mr. H.C. Floyd  
Mr. Alan Fodor  
Fogelberg Foundation of Peoria  
Mr. William Fogle  
Ms. Penny Foley  
Donald Folgner  
Mr. and Mrs. Robert B. Forsland  
Mr. Michael S. Franklin  
Mr. Philip Friedmann  
Dr. and Mrs. Mark H. Fritze  
Mr. and Mrs. William Frumkin  
Mr. Daniel K. Fry  
Fuccillo Affiliates of Florida -  
Fuccillo Kia of Cape Coral  
Ira and Anna Galkin Charitable Trust  
Mr. and Mrs. J. Donald Garvey  
Mr. Robin Gates and Ms. Jan Fulwiler  
Dr. Theodore L. Gerstl  
Mr. Gerald Gibian  
Mr. and Mrs. Robert Gill  
Mr. Dion Giolito  
Giuliani Deason Capital Interests, LLC  
Mr. Patrick Glenn  
Ms. Suzanne Gold  
Mr. David Goldenberg  
Mr. Myles Goldfein  
Ellen M. Golub Charitable Foundation  
Melvin R Goodes Family Foundation  
Ms. Nancy Goodes  
Ms. Heather M. Gosnell  
John P. Gould and  
Kathleen A. Carpenter  
Mr. and Mrs. Jonathan P. Goulding  
Mr. Steven Grandin  
Mr. Bill Green  
Richard J. Green and Firstrust Bank  
Mr. Robert Green, Jr.  
Madison Gulley  
Mr. Richard Haddrill  
Mr. Robert T. Haenggi  
Mr. Tarek Hallaba and  
Mrs. Nahed Hallaba  
Ms. Julie A. Hansen  
Mr. Brian Harris  
Ms. Jennifer J. Hartland  
HDR  
Mr. Michael Headley  
Mr. and Mrs. Steven Headley  
Dr. Roger W. Helfrich and  
Mrs. Erica Helfrich  
Ms. Barbara Jean Helvie  
Hempstead Senior High School  
Mr. and Mrs. H. Peyton Henderson  
Dr. and Mrs. George Henrichson  
William Henry Trust  
Mr. Howard Hertz  
Lisa Winston Hicks  
Steven Higger

Ms. Leah Hindy  
 Mr. Paul E. Hirschauer  
 Dr. and Mrs. Michael Hirsig  
 Dr. and Mrs. Stuart Holden  
 Mrs. Debra Holstein  
 The William E. and Audrine C. Honey Foundation, Inc.  
 Dr. and Mrs. Leo Nelson Hopkins  
 Mr. and Mrs. Larry Horn  
 Mr. and Mrs. Norman Hurt  
 Mr. William P. Hypes  
 Steve Iverson  
 Mr. Stephen L. Jacobs  
 JALS Foundation  
 Mr. and Mrs. Daryl L. Jespersen  
 Mr. and Mrs. John Jester  
 Jones Family Foundation  
 Ms. Kimberlee Jones  
 The J.P. Morgan Chase Foundation  
 Kane Corporation  
 Mr. Jamie Kaplan and  
 Ms. Suzanne Meecker  
 Mr. Ira Katz  
 Mr. Mitchel Katz and  
 Mrs. Meredith Katz  
 Mr. Jeffrey A. Kaufman  
 Mr. Jack Keller  
 Kennedy Marketing Group  
 Heidi and Randy Keogh  
 Mrs. Rebecca Kepner  
 The Kirschner-Bookatz Family  
 Foundation, a Supporting  
 Foundation of the Dallas Jewish  
 Community Foundation  
 Mr. George D. Kittredge  
 James W. Klein  
 Mr. Lloyd Klein  
 Arlene and Michael J. Klosk  
 Harold and Shirley Kobliner  
 Mr. Michael Koehnen  
 Mr. Christopher A. Krack  
 Mr. Richard S. Kramer  
 Mr. Steven Kremesec  
 Raymond and Barbara Krueger  
 Dottie and Tom Krull  
 Mr. and Mrs. Frank Kulze  
 LA-CO Industries, Inc.  
 La Verne Police Officers Association  
 Mrs. Donna M. Lashock  
 Dr. and Mrs. Robert H. Lawrence, Jr.  
 Mr. and Mrs. Dennis Leuthauser  
 Craig & Carrie Levering  
 Charitable Foundation  
 Mr. Joshua H. Levine  
 Dr. Brian L. Levy  
 Loida Nicolas Lewis  
 Ms. Victoria Lika  
 Mr. and Mrs. Robert Limburg  
 Mr. and Mrs. Todd K. Lindsey  
 Mr. Robert J. Lischak  
 Ms. Debra Livengood  
 Mr. Chris Lloyd  
 Mr. Don Loeb and Mrs. JoEllen Loeb  
 Mr. and Mrs. Gerald A. Long  
 Mr. Bradley Look  
 Chris and Krista Loose  
 Douglas Lowe  
 Charles Lowrey and Susan Rodriguez  
 Mrs. Sandra Lucchesi  
 Gordon Maahs  
 Mr. Con Mallon  
 Mr. Jacob Mandel  
 Mr. Thomas Mandel  
 Mr. and Mrs. Ralph B. Mandell  
 Mr. Arnold J. Mangen  
 Leslie B. Mann  
 Mr. Robert Mansfield and  
 Mrs. Patricia Mansfield  
 Mr. William Daryl Marcum  
 Dr. Philip Marcus and  
 Mrs. Marcia Marcus  
 Mr. John H. Marshall  
 Mr. Douglas G. Martin  
 H. Gordon Martin Foundation  
 Mr. James Martin  
 Mr. Charles W. Martindale  
 Mr. Phil Maxfield and  
 Mrs. Bella Maxfield  
 Mr. Ullrich Mayeski  
 Michele McBride and Michael Barile  
 McCown Family Foundation  
 Mr. James McIlree  
 James and Ann McKinney  
 Laureston and Barbara McLellan  
 McMillan & Associates, LLC  
 Mr. and Mrs. Harry McMillan/  
 McMillan and Associates  
 Mr. William B. McNamara  
 Mr. Dan McPartlin and  
 Mrs. Dollie McPartlin  
 Mr. and Mrs. Thomas McPherson  
 Major General McVey, U.S. Army (Ret.)  
 and Mrs. McVey  
 Mr. and Mrs. Joseph M. Mego  
 Ms. Barbara J. Meislin  
 Mrs. Wayne Meling  
 Ms. Nancy Menezes  
 Joseph Salvatore Merola Living Trust  
 Mr. and Mrs. Jack Meyers  
 Mr. Peter Meyer  
 Middlesex County Sheriffs Officers  
 PBA Local 165  
 Mr. Paul J. Milbury  
 Lowell Milken Family Foundation  
 The John A. Miller Family Foundation  
 Mr. and Mrs. Theodore N. Miller  
 Adam and Gila Milstein  
 Family Foundation  
 Mr. Robert R. Monaco  
 Dr. and Mrs. R. Bruce Montgomery  
 Ms. Natasha Moore  
 Mr. Robert L. Moore  
 Linda and Michael Morgan  
 Mr. and Mrs. Paul R. Murphy  
 Mr. Ujjual Nath  
 Mr. Daniel Nelson  
 Mr. Richard Nessary  
 Mr. and Mrs. Michael Nestor  
 Blake Lee and Carolyn L. Neubauer  
 Carol and Reg Newman  
 Mr. Jerrod Newsom  
 Karen Preble Nichols  
 Mr. and Mrs. Scott G. Nichols  
 Ms. Fernanda W. Niven  
 Mr. and Mrs. John Norwood  
 Dr. and Mrs. James E. O'Brien  
 Mr. and Mrs. Stephen T. O'Brien  
 Mr. Gregory S. Oberholtzer  
 Mr. Robert Oblock  
 Mr. David Ogrin  
 Mr. and Mrs. Henry Ondrusek  
 Mrs. Sureshrani Paintal  
 Mr. and Mrs. Louis Franklin Parsley, III  
 Mr. and Mrs. Charles A. Partain  
 Mario and Alma Pastega  
 Family Foundation  
 Mr. Phillip Patch  
 Thomas J. Patrician  
 Mr. Ernesto Perez-Carrillo  
 Mr. Craig Peskin  
 Daniel P. Petrylak, MD  
 Phillies Charities, Inc.  
 Jennifer and Ken Phillips  
 Mr. and Mrs. James T. Pizzo  
 Pledgeling Foundation  
 Mr. Adam Plissner  
 The Poth Family  
 Dr. and Mrs. Andrew G. Poulos  
 Ms. Angela Putman  
 Quad/Graphics Inc.  
 The Rabin Foundation  
 The Rabinowitz Foundation  
 Marc and Sheri Rapaport  
 Mr. and Mrs. Warren Rasmussen  
 Mr. Rudolph Rehm  
 Mr. James A. Reinig and  
 Mrs. Christina A. Reinig  
 Mr. Steve Renehan  
 Mr. Jonathan Rettinger  
 Mr. and Mrs. John N. Richardson, Jr.  
 Major Charles N. Riley  
 Mr. Daryl Rix  
 Drs. W. Scott and Karen T. Robertson  
 Mr. Alfred Rose  
 Mr. Michael Rose  
 Mr. Roger Rose and  
 Mrs. Margaret Rose  
 Mr. and Mrs. Robert Rosenberg  
 Mr. James A. Roth and  
 Mrs. Nancy S. Roth  
 Mr. Samuel Rotondo  
 Mr. Alan Rubin / Alec Bradley Cigars  
 Mr. and Mrs. Chris J. Rufer  
 Mr. Robert Ryall  
 Connie Ryan and Carrie Kreifels  
 Mr. Timothy P. Ryan  
 Mr. Skip Sack and Mrs. Gail Sack  
 Mr. James Sadowski  
 Dr. and Mrs. Fulton L. Saier  
 Dr. and Mrs. Robert N. Saito  
 Samford University  
 Mr. Richard S. Sauers  
 Mr. and Mrs. John E. Schlitt  
 Douglas and Jennifer Schoen  
 Mr. Paul H. Sears  
 David Seewack  
 Mr. and Mrs. Michael F. Shanley  
 Mr. John Shannon  
 Mr. Steven Shaw  
 Mr. William Shenkman and  
 Mrs. Maureen Shenkman  
 Mr. E. Michael Shine  
 Mr. Yves Siegel  
 Mr. and Mrs. Walton A. Silver  
 Mr. Jon Skidmore and  
 Mrs. Lisa Skidmore  
 Mrs. Mary A. Sklenar  
 Marilyn and Lee Snider  
 Mr. Carl Soderstrom  
 Mr. David B. Solberg and  
 Mrs. Sandra I. Solberg  
 Mr. Andrew Solomon  
 Mr. and Mrs. Michael A. Sommer  
 Mr. John C. Sowa  
 Irwin and Lorri Spiegel  
 Mr. Robert I. Spiegel  
 Mr. Richard D. Squires  
 Mr. Richard Miles Stanislaw  
 Michael Stars Foundation  
 State Legislative Leaders Foundation  
 Mr. Russell Stidolph  
 Ms. Jacqueline Stone  
 Stotz Equipment  
 Mrs. Catherine Stupski  
 Mr. Ronald Styn  
 Mr. J. Wayne Suarez  
 Mr. and Mrs. Michael Sullivan  
 Mr. Trent Sunde and Mrs. Patti Sunde  
 Sunnyland Bulgur Wheat, Inc.  
 Mr. Jack R. Swain, III  
 Mr. Arthur L. Swint  
 Mr. and Mrs. Richard Szilasi  
 Mr. Russell M. Tahmoush  
 Mr. Richard A. Tanovich  
 TAR Holdings, LLC  
 Mr. Kevin Taweel  
 Stephen G. Tolchin  
 Mr. Pascal F. Tone  
 Fiona and Dr. Bob Toth  
 Mr. Peter L. Townsend  
 Troutman Sanders, LLP  
 Lawrence D. True, MD  
 Mr. Wesley Tull  
 Mr. James J. Turner  
 Mr. and Mrs. Knight Tuttle  
 Ms. Darci F. Tyson  
 UGI Energy Services, LLC  
 Mr. Russell Underwood  
 UniHealth Foundation  
 The VanAllen Group  
 Mr. James Vanlandingham  
 Mr. Jerome Vaughan  
 Meryle and Daniel Verner  
 Mr. and Mrs. David B. Vodden  
 Mr. James Walker  
 Mr. Timothy Ray Wallace  
 Mrs. Richard Warren  
 Mr. and Mrs. Charles Wax

Mr. Michael Weber  
 Mr. Jon Webster  
 Michael and Jill Weinstein  
 Mr. Steven B. Weinstein  
 Dr. Richard E. Weisblatt  
 Mr. Richard Wesslund and  
 Mrs. Maria Wesslund  
 Mr. and Mrs. Nigel Weston  
 Mrs. Janet O. White  
 Whiting Petroleum Corp.  
 Mr. Henry Wilf  
 The Wine Institute  
 Mr. and Mrs. John Winkel  
 Matthew and Elizabeth Winkler  
 The Winning Ways Foundation  
 Mr. Henry Winterstern  
 Mr. Gerald A. Wolff  
 Mr. and Mrs. Bruce Wooley  
 Ms. Vita Yakim  
 Mr. and Mrs. Harry Yeaggy  
 Mrs. Adele Z. Younkim  
 Mrs. Darcy Zalewski  
 Mr. Gary Zellerbach  
 Mr. and Mrs. Stanley M. Zimmerman  
 Mr. David Zinke

### Many vs Cancer Fundraisers

*Participants who raised \$1,000 or more*

Andrew J. Astrachan  
 Brett Kurland  
 Ian McLeod  
 Shmuel Meitar  
 Matthew Nesto  
 Richard Prego  
 Jason Safriet  
 Ramiro Siliezar  
 Jeff Zisk

### Special Partnerships and Hosted Events

*Special partnerships or hosted events that raised \$1,000 or more*

3rd Annual AWLG Cornhole  
 Tournament at Crop Production  
 Services in Loveland  
 3rd Annual Jerrod Newsom Event  
 3rd Annual Simon Says Run for  
 Prostate Cancer  
 4th Annual Santa Cruz Stache Dash  
 4th Annual Ted Hughes Memorial  
 BattleLax Tournament  
 7th Annual Deric's Day at Thunderhill  
 Accuray  
 Alpha Chi Alpha  
 Anderson Merchandisers, LLC  
 Anglers For The Cure  
 AZ State Rifle and Pistol Association  
 - Shotgun Division  
 4th Annual "Blue Ribbon Clays"  
 Tournament  
 Bayport Blue Point HS Soccer team  
 fundraiser, led by team captain  
 Joshua Lurie, in honor of Coach  
 Bobby Schmipf

Blank Rome LLP's September  
 Jeans Day  
 Cali Holak's backyard prostate cancer  
 awareness fundraiser  
 Castle Heights Elementary "Steps  
 That Care"  
 Chicago Fire Department Stache Bash  
 Deacon Corporation Event  
 Embrace Hospice's No Shave  
 November  
 Employees of Trone Brand Energy  
 Fleetwood Area Middle School  
 Student Council Fundraiser  
 GoAZ Motorcycles Vintage Bike Show  
 Groove Phi Groove  
 Hawg Valley Bike Rally August 2016  
 Hempstead Senior High School  
 Holy Cross Lutheran Church  
 Ian McLeod Fundraiser  
 Moravian College Baseball Team's  
 Strikeout Prostate Cancer "Blue  
 Out" Baseball Game  
 North Haledon PBA Local 292  
 Drew Okun's Mitzvah Project  
 RollerCon  
 Samford University  
 St. Tammany Parish Sheriff's Office  
 Employee Fundraisers  
 SCW Fitness Education Mania Charity  
 TMNA Services, LLC Jeans Day  
 Troutman Sanders, LLP's "Denim and  
 Donations" Program  
 UGI Energy Services and  
 its Employees  
 USA Volleyball  
 Washington Township High School  
 Wenatchee High School - ASB  
 Willy McGee's Pub & Eatery  
 Wings-Giving at Mudville 9, hosted by  
 Limitless Events NYC  
 Winton Middle School  
 Student Fundraising  
 The Worship Center of KC  
 Xavier High School Cancer  
 Awareness Week  
 Yough High School's Softball Team's  
 "Strike Out Cancer"

### Blue Ribbon Golf Tournaments

*Golf tournaments that raised \$1,000 or more*

1:31 Sabal Springs Club Charity  
 Golf Tournament  
 11th Annual Faith, Love, Hope, Win  
 (FLHW) Golf Tournament  
 11th Precinct Community Council  
 4th Annual DIII Father's Day Golf  
 Tournament (Forest Hills  
 Golf Course)  
 9th Annual Pros4Care Golf and  
 Motorcycle Event  
 19th Hole Classic  
 A Charity Challenge at Broken  
 Sound, Inc.  
 Addison Reserve Country Club  
 Alpha Tau Omega Golf Tournament

Bella Vista Country Club  
 Golf Tournament  
 Burlington Golf Club  
 C.A.R.E. Golf Outing  
 Carolina Trace Country Club  
 Chasing the Sun Challenge -  
 Dandoy Father/Son  
 Colonial Cup Tournament (Camden  
 Country Club)  
 Concordia Golf Club  
 Don't Stop Believin' Invitational -  
 SDGCSAA  
 Friends of Aramark Golf Tournament  
 Glow-in-the-Dark Golf Tournament  
 for PCF  
 Golfers Against Cancer  
 Heritage Palms Men's Niners  
 Golf Club  
 Herons Glen Golf & Country Club  
 Highland Meadows Country Club  
 HLT Texas Shootout  
 Indian Summer CC Member-Guest  
 ILWU Tri-Party Challenge  
 Iron Lakes Country Club  
 Jay Moody Memorial Golf Tournament  
 Jonathan's Landing Golf Club  
 Katemaya Country Club  
 Lago Vista Golf Course  
 Lehigh Valley (Lords Valley  
 Country Club)  
 Lobster Classic  
 Luetzow Charity Golf Outing at  
 Stoney Links  
 Marlborough CC Women's Golf Sadie  
 Hawkins Tourney  
 Meadow Club  
 Palm Aire Country Club  
 Palm Beach Polo Golf & Country Club  
 Paupack Hills Golf and Country Club  
 Pelican Pointe Golf & Country Club  
 Prostate Cancer Invitational  
 at Loveland  
 Prostate Partners Golf Tournament  
 (Highland Woods G&CC)  
 Rarity Bay Golf Club  
 Rio Verde Country Club  
 Sheffield Pharmaceuticals Golf  
 Tournament for Prostate Cancer  
 Southfield Silhouettes  
 Steve Hiron Memorial  
 Golf Tournament  
 Sweetwater Community Men's  
 Cancer Tournament  
 Terravita Golf Club  
 University Park Country Club  
 Wild Dunes Golf Resort  
 Member-Guest  
 Wycliffe Golf & Country Club

### Blue Ribbon Society

*Our community of monthly donors*

Mr. Steve M. Abbott and  
 Mrs. Diana M. Abbott  
 Mr. Roy E. Acer  
 Mr. Donald Allen  
 Mr. Paul N. Anderson

Mr. Norman B. Antin  
 Mr. and Mrs. M. Douglas Asher  
 Mr. and Mrs. Frederick G. Bailine  
 Mr. Louis A. Baldock  
 Mr. Keith Bertolino  
 Mrs. B.G. Bramley  
 Mr. Sidney Brandt  
 Mr. Robert T. Brew, Jr.  
 Mr. and Mrs. Grant Brown  
 Mr. Kyle E. Brown and  
 Mrs. Jeanette Brown  
 Ms. Rebecca Brown  
 Mr. and Mrs. Stuart Brown  
 Beth C. Burdick  
 Mr. and Mrs. Henry Burk  
 Ms. Patricia Burton  
 Mr. and Mrs. Danny Byler  
 Frank and Adrienne Cardone  
 Mr. David P. Carosella  
 Mr. Daniel Chapman  
 Mr. Scott Chaudoir  
 Mr. and Mrs. Cory Compton  
 Mr. Justin A. Coombs  
 Mr. and Mrs. Stephen Comes  
 Mr. Craig J. Couture  
 Mr. Bruce Cox  
 Mr. Jeffery Cundick  
 Mr. Baron Curtis  
 Ms. Wendy E. Danaher  
 Mr. Paul Darnauer and  
 Mrs. Micki Darnauer  
 Mr. Donald H. Davis  
 Mr. Kirby Deines  
 Ms. Dorothy Delarm  
 Mr. Todd J. Dokken  
 Ms. Lark E. Draper  
 Mr. James A. Dusek  
 Mr. and Mrs. Willard Easton, Jr.  
 Mr. Kenneth L. English  
 Mr. and Mrs. Millison Fambles  
 Mr. Martin Fishbaugh  
 Mr. Richard Fournier  
 Mr. and Mrs. Michael R. Franchio, II  
 Mr. Daniel K. Fry  
 Mr. Max Fuentes  
 Ms. Jayme Garbo  
 Mr. and Mrs. John L. Garvin  
 Mr. Ryan Gilmartin  
 Mr. Stanley A. Glassman  
 Mrs. Joyce Gonzales  
 Mr. Gary M. Goodfriend  
 Mr. and Mrs. Robert Greenbaum  
 Gerry and Herb Greenman  
 Mr. Michael D. Grills  
 Mr. Lloyd Lacey Haley  
 Mr. James G. Hammond  
 Mrs. Verna Hammond  
 Ms. Julie A. Hansen  
 Mr. Kent L. Hastings and  
 Mrs. Libby Hastings  
 Mr. and Mrs. William R. Hasty  
 Mr. Michael L. Hawley and  
 Mrs. Patricia D. Hawley  
 Mr. Barry L. Heath



Mr. and Mrs. Jeffrey Hess  
 Mr. Bradford L. Hillegass  
 Mr. Bob Hodges  
 Mr. and Mrs. Michael R. Hund  
 Mrs. Christine M. Hunter  
 Ms. Alexandria M. Ivancic  
 Lt. Luke W. Jean  
 Mr. Randall John  
 Mr. and Mrs. Mark W. Johnson  
 Mr. and Mrs. Robert A. Johnson  
 Mr. Gerald O. Jones  
 Ms. Kimberlee Jones  
 Mr. Roger A. Jones  
 Mr. and Mrs. Tom Joplin  
 Dr. and Mrs. Robert R. Jorgensen  
 Mr. and Mrs. Michael I. Joseph  
 Mr. and Mrs. Joseph Katz  
 Dr. and Mrs. Douglas W. Keiser  
 Mr. Damian J. Kelly  
 Dr. David Kenworthy and  
 Mrs. Sharon Kenworthy  
 Mr. William D. Kleeman  
 Mr. Edward M. Koch, Jr.  
 Dr. Robert A. Kraft  
 Mr. Daniel Krider  
 Mr. and Mrs. Damian Kucharik  
 Mr. Albert Latini  
 Mrs. Janet Lehoullier  
 Mr. Steven Leonido-John  
 Mr. and Mrs. Todd Lewandowski  
 Mr. Robert H. Linsey  
 Dr. David L. Livingston  
 Mr. Jack Loeb, Jr.  
 Mrs. Beatrice Ann Luthringer  
 Mr. James MacDonald  
 Richard F. Mackey  
 Mr. Jacob Mandel  
 Mr. Allan C. Marshall  
 Mr. Dean K. Mathis  
 Mr. and Mrs. Kenny D. Maynes  
 Mr. Joseph Mazzeo  
 Mr. and Mrs. James McCann  
 Profs. Michael and Kathryn McCarthy  
 Mr. Sean McKee and  
 Mrs. Diane McKee  
 Mr. James McNasby  
 Mr. and Mrs. Tom Meskel  
 Mr. Arthur N. Michell  
 Mr. John Mihalchik  
 Mr. Dean Minard  
 Ms. Denise Moad Hollingsworth  
 Mr. Freeman M. Montaque, Jr.  
 Mr. Dennis G. Morgan  
 Mr. Scott Morgan and  
 Mrs. Rhonda Morgan  
 Mr. John E. Moseley  
 Ms. Maeve Nolan  
 Mr. Francis Jerry Norder  
 Mr. Raymond V. O'Connor, Jr.  
 Mr. John O'Shea and  
 Mrs. Patricia O'Shea  
 Mrs. Mary H. Ott  
 Mr. Gregg H. Overman and  
 Mrs. Leona Strizich Overman

Ms. Lisa Palumbo  
 Mr. Richard A. Parrish  
 Mr. and Mrs. William W. Prior, Sr.  
 Mr. Frank Quale  
 Elder Aurelius Raines, Sr.  
 Mr. and Mrs. John M. Randall  
 Mr. Marcio L. Rangel  
 Dr. and Mrs. Ralph J. Rauch  
 Mr. Riley Rice  
 Ms. Joanna M. Rizzo  
 Mr. and Mrs. Richard Roberson  
 Mr. Kenneth I. Rose, III  
 Mr. and Mrs. Thomas A. Sawyer  
 Mr. Michael A. Sekyra  
 Mr. Michael Sellers  
 Mr. Robert H. Sherman and  
 Mrs. Corrine Sherman  
 Mr. Phillip Short  
 Mr. Alan E. Shrefler  
 Mr. Thomas Skleba  
 Mr. Brian D. Smith  
 Mr. Mark C. Smith  
 Mr. Mike Smith  
 Capt. Stanley D. Smith  
 Mr. Larry Souder  
 Mr. Lee Stahl  
 Mr. Leland L. Stanford  
 Mr. and Mrs. William E. Stegall  
 Lesley and Robert Stern  
 Gary Stoneburner  
 Mr. and Mrs. Donald Stroh  
 Mr. Michael Sugg  
 Mr. and Mrs. Richard Szilasi  
 Mr. Hal J. Templin  
 Mr. Paul Thiede  
 Mr. Belal M. Tiba  
 Mr. George C. Torres and  
 Mrs. Colette Torres  
 Mr. Duane E. Trump and  
 Mr. Edan Trump  
 Mr. and Mrs. Thomas R. Utesch  
 Mr. Heinrich Vaseur  
 Mrs. Marion E. Wade  
 Mr. Kevin Webb  
 Mr. and Mrs. Howard J. Willis  
 Mr. and Mrs. Wayne K. Wilson  
 Mr. Ken Wiseman  
 Mr. Leslie Wood  
 Mrs. Patricia Yearick  
 Mrs. Darcy Zalewski  
 Mr. Robert F. Zuppert Jr. and  
 Mrs. Emily Zuppert

**Memorial Tribute Funds**  
*Funds that contributed \$1,000 or more*

**In Memory of:**

William J. Alspaugh  
 Roger B. Anderson  
 Wayne R. Anderson  
 James F. Bauer  
 Charles Bennett  
 Francis E. Burke  
 James H. Carter, Sr.  
 Paul Cotton

Kevin W. Crowley  
 Thomas F. Delaney  
 Derric D. DesMarteau  
 Peter A. Dierickx  
 Walter J. Donheiser  
 David Federman  
 Theodore H. Fenske, Jr.  
 Daniel G. Fogelberg  
 Conrad R. Freund  
 Harvey "George" Gangler, Jr.  
 Gary G. Gentile  
 Robert T. Gilhuly  
 John G. Gilmour  
 William M. Ginty  
 Jerome A. Gold  
 Ellen Golub  
 Robert E. Goulding  
 Peter D. Grimm  
 Billy M. Hargis  
 Paul C. Helfrich  
 Sebastiaan W. Hofland  
 Edward J. Hughes, Jr.  
 Gary Jones  
 Thomas E. Jones  
 Michael T. Kennedy  
 Rowan K. Klein, Sr.  
 Shirley Kobliner  
 Bradley G. Lashock  
 Mario Leonetti  
 William L. Mackintosh  
 Jack McGetrick  
 Charles E. McGrigg  
 Joseph Merola  
 Richard & Barbara Meyer  
 Peter Michels  
 E. Michael Moore  
 Philip C. Murray  
 Ray N. Norwood  
 Ezra Novak  
 Arthur Orenstein  
 Carl P. Orlando  
 Brien Palmer  
 Leo B. Pedrotty, Sr.  
 Robert E. Preble  
 Donald E. Riesbeck  
 David M. Riley  
 Robert Rix  
 Charles W. Robison  
 Giovanni S. Romano  
 Leonid Rozin  
 Marc Sablow  
 Leslie J. Sacks  
 Robert P. Sadowski  
 James H. Scheper  
 Scott L. Schubel  
 Alan Solomon  
 Reed Somberg  
 Jim Spain  
 Verne M. Spangenberg  
 C. Fred Sperber  
 Lawrence J. Stupski  
 Dr. Robert J. Temple  
 Philip M. Theisen  
 William M. Thompson, Jr.

Deacon William Umphress  
 Joe Underwood  
 Jerry Weintraub  
 Richard A. White  
 Cathy Wice  
 Grandpa Wild  
 Norman R. Wiles  
 Kenneth C. Winkleblack  
 Robert Wydra

**Honorary Tribute Funds**  
*Funds that contributed \$1,000 or more*

**In Honor of:**

21st Century Oncology  
 Dr. Elliot Abramowitz  
 Jay Allen  
 Mike Arnold  
 Andrew J. Astrachan  
 Christopher E. Barry  
 Anthony Boule  
 Allan Christensen  
 Stephen S. Cole  
 David A. Ederer  
 Ralph Finerman  
 Sam Hill  
 Robert Jee  
 Stuart Kaplan  
 Lawrence Kurland  
 Vincent Lombardi  
 Simon McKee  
 Neil McLeod  
 Jerry Meislin  
 Michael Milken  
 John Milko  
 James B. Nebel  
 James Newsom  
 Dr. Brian T. O'Hallaren  
 PAC, LP  
 Wendell Putman  
 Bobby Schimpf  
 Nelson Schwab  
 Jonathan W. Simons, MD  
 Howard R. Soule, PhD  
 Richard L. Starkey  
 Dennis Thorpe  
 Wesley Tull, Sr.  
 Kneeland Youngblood

*Represents annual donations  
 (gifts, not pledges) between  
 January 1, 2016 and  
 December 31, 2016.*

# 2016 RESEARCH AWARDS

## Expanding PCF's Global Research Enterprise



Photography: Paul Bliese

PCF Young Investigators attended the 23<sup>rd</sup> Annual PCF Scientific Retreat and shared their unpublished data.

### PCF YOUNG INVESTIGATOR AWARDS

The achievements of PCF Young Investigators represent some of the most game-changing work in all of cancer research. They keep the field of prostate cancer research vibrant with new ideas. In 2016, PCF funded 26 new Young Investigators. By mid-year 2016, PCF had funded a total of 204 Young Investigators since the program began in 2007.

#### 2016 Elliot Abramowitz-PCF Young Investigator Award

Rohit Bose, MD, PhD  
Memorial Sloan Kettering Cancer Center, New York, NY

#### 2016 David Yurman-PCF Young Investigator Award

Ginevra Botta, PhD  
Harvard: Dana-Farber Cancer Institute, Boston, MA

#### 2016 Art Kern-PCF Young Investigator Award

Albert Chang, MD, PhD  
University of California, San Francisco, San Francisco, CA

#### 2016 Shelley Shorsch-PCF Young Investigator Award (Funding Year 1 of 3)

Alastair Davies, PhD  
University of British Columbia, Vancouver, BC

#### 2016 Marjorie Katz-PCF Young Investigator Award

Renée de Leeuw, PhD  
Thomas Jefferson University, Philadelphia, PA

#### 2016 Mark Walter-PCF Young Investigator Award

(Funding Year 1 of 3)  
Eleonora Dondossola, PhD  
The University of Texas MD Anderson Cancer Center, Houston, TX

#### 2016 Neal Rodin-PCF Young Investigator Award

Christopher Kloss, PhD  
University of Pennsylvania, Philadelphia, PA

#### 2016 Debbie and Mark Attanasio- PCF Young Investigator Award

Christos Kyriakopoulos, MD  
University of Wisconsin, Madison, WI

#### 2016 Lew Katz-PCF Young Investigator Award

David Labbé, PhD  
Harvard: Dana-Farber Cancer Institute, Boston, MA

#### 2016 Shmuel Meitar-PCF Young Investigator Award

H. Benjamin Larman, PhD  
Johns Hopkins University, Baltimore, MD

#### 2016 Tom Murphy–PCF Young Investigator Award

Stacy Loeb, MD  
New York University, New York, NY

#### 2016 Stewart Rahr–PCF Young Investigator Award

Reem Malek, PhD  
Johns Hopkins University, Baltimore, MD

#### 2016 Lew Katz–PCF Young Investigator Award

Mark Markowski, MD, PhD  
Johns Hopkins University, Baltimore, MD

#### 2016 Art Kern–PCF Young Investigator Award

Joaquin Mateo, MD  
Institute of Cancer Research, The Royal Marsden Hospital, London, England

#### 2016 Lew Katz–PCF Young Investigator Award

Sean McBride, MD  
Memorial Sloan Kettering Cancer Center, New York, NY

#### 2016 Maureen and Steve Klinsky–PCF Young Investigator Award

David Miyamoto, MD, PhD  
Harvard: Massachusetts General Hospital, Boston, MA

#### 2016 PCF-AUA-SUO Young Investigator Award

Hao Nguyen, MD, PhD  
University of California, San Francisco, San Francisco, CA

#### 2016 Seth Bernstein–PCF Young Investigator Award

Russell Pachynski, MD  
Washington University, St. Louis, MO

#### 2016 Lori Milken–PCF Young Investigator Award

Loredana Puca, PhD  
Weill Cornell Medicine, New York, NY

#### 2016 Astellas and Medivation–PCF Young Investigator Award

Steven Rowe, MD, PhD  
Johns Hopkins University, Baltimore, MD

#### 2016 Jonathan Steinberg–PCF Young Investigator Award

Simpa Salami, MD, MPH  
University of Michigan, Ann Arbor, MI

#### 2016 Elaine Wynn–PCF Young Investigator Award

Bryan Smith, PhD  
University of California, Los Angeles, Los Angeles, CA

#### 2016 Art Kern–PCF Young Investigator Award

Jean Tien, PhD  
University of Michigan, Ann Arbor, MI

#### 2016 Clay Hamlin–PCF Young Investigator Award

Quoc-Dien Trinh, MD  
Harvard: Brigham and Women's Hospital, Boston, MA

#### 2016 Laurie and Peter Grauer–PCF Young Investigator Award

Hung-Ji Tsai, PhD  
Johns Hopkins University, Baltimore, MD

#### 2016 Ray Chambers–PCF Young Investigator Award

Jelani Zarif, PhD  
Johns Hopkins University, Baltimore, MD

#### 2015 Larry Gagosian–PCF Young Investigator Award

(Funding Year 2 of 3)  
Justin Drake, PhD  
Rutgers University Institute of New Jersey, New Brunswick, NJ

#### 2015 Eustace Wolfington–PCF Young Investigator Award

(Funding Year 2 of 3)  
Joseph Ippolito, MD, PhD  
Washington University, St. Louis, MO

## PCF CHALLENGE AWARDS

In 2016, 20 Challenge Award teams were funded by the Foundation. Through peer reviews, PCF selected these projects out of 55 proposals from highly qualified research teams at 43 prestigious cancer centers located in three countries. The Class of 2016 Challenge Awards represents an investment of \$19.2 million in advanced prostate cancer research.

### 2016 Movember Foundation–PCF Challenge Awards

#### Co-Principal Investigators:

Gerhardt Attard, MD, PhD  
Institute of Cancer Research, London, England

Himisha Beltran, MD  
Weill Cornell Medicine, New York, NY

Kim Chi, MD  
University of British Columbia, Vancouver, BC

Francesca Demichelis, PhD  
Università degli Studi di Trento, Trento, Italy

Alessandro Romanel, PhD  
Università degli Studi di Trento, Trento, Italy

Mark Rubin, MD  
Weill Cornell Medicine, New York, NY

Eliezer Van Allen, MD  
Harvard: Dana-Farber Cancer Institute, Boston, MA

Alexander Wyatt, PhD  
Vancouver Prostate Centre, Vancouver, BC

*Goal: Development of a liquid biopsy-based genomics sequencing test that identifies tumor mutations and can be used to guide selection of precision medicine treatments for patients*

#### Co-Principal Investigators:

Hongwu Chen, PhD  
University of California, Davis, Davis, CA

Christopher Evans, MD  
University of California, Davis, Davis, CA

*Goal: Development of a potent new therapy for castrate-resistant prostate cancer patients that targets ROR-gamma, a molecular partner of the androgen receptor*

*Co-Principal Investigators:*

**Andrew Hsieh, MD**

Fred Hutchinson Cancer Research Center, Seattle, WA

**Brett Carver, MD**

Memorial Sloan Kettering Cancer Center, New York, NY

**Yu Chen, MD, PhD**

Memorial Sloan Kettering Cancer Center, New York, NY

**Goal: Advancement of precision medicine by matching various mutations in the cancer-driving PI3K pathway to different PI3K pathway-targeted treatments**

*Principal Investigator:*

**Kenneth Pienta, MD**

Johns Hopkins University, Baltimore, MD

**Goal: Development of methods to identify patients who have prostate cancer cells that have metastasized to bone sites but have not yet grown into tumors and guide their treatment**

*Co-Principal Investigators:*

**Russell Taichman, DMD**

University of Michigan, Ann Arbor, MI

**Laura Buttitta, PhD**

University of Michigan, Ann Arbor, MI

**Todd Morgan, MD**

University of Michigan, Ann Arbor, MI

**Kenneth Pienta, MD**

Johns Hopkins University, Baltimore, MD

**Goal: Identification of the genes most critical to the establishment and growth of prostate cancer bone metastases, and credentialing those which are promising therapeutic targets**

## 2016 PCF Challenge Awards

### 2016 Victoria and Vinny Smith-PCF Challenge Award

*Co-Principal Investigators:*

**Arul Chinnaiyan, MD, PhD**

University of Michigan, Ann Arbor, MI

**Elizabeth Heath, MD**

Wayne State University, Detroit, MI

**Goal: Development of a novel multi-tyrosine inhibitor, ESK981, as a new treatment for metastatic castrate-resistant prostate cancer**

### 2016 Victoria and Vinny Smith-PCF Challenge Award

*Co-Principal Investigators:*

**Johann de Bono, MD, PhD**

Institute of Cancer Research, The Royal Marsden Hospital, London, England

**Myles Brown, MD**

Harvard: Dana-Farber Cancer Institute, Boston, MA

**Andrew Kato, PhD**

Karlsruhe Institute of Technology, Karlsruhe, Germany

**Stephen Plymate, MD**

University of Washington, Seattle, WA

**Goal: Determination of whether disrupting the interaction between the androgen receptor and its protein partner BAG-1 will be an effective therapeutic strategy, and development of novel therapeutic compounds to achieve this in patients**

### 2016 Judy and David Fleischer-PCF Challenge Award

*Co-Principal Investigators:*

**Lawrence Fong, MD**

University of California, San Francisco, San Francisco, CA

**Felix Feng, MD**

University of California, San Francisco, San Francisco, CA

**Goal: Development of a new treatment strategy combining androgen deprivation therapy, radiation therapy, and pembrolizumab immunotherapy for patients at early stages of metastasis**

### 2016 Astellas and Medivation-Loyd and Jeff Zisk-PCF Challenge Award

*Co-Principal Investigators:*

**David Karow, MD, PhD**

University of California, San Diego, San Diego, CA

**Donna Hansel, MD, PhD**

University of California, San Diego, San Diego, CA

**Christopher Kane, MD**

University of California, San Diego, San Diego, CA

**Goal: Development of a novel molecular imaging technology, Restriction Spectrum Imaging-Magnetic Response Imaging (RSI-MRI), for detecting metastatic prostate tumors**

### 2016 Stewart J. Rahr Foundation-PCF Challenge Award

*Co-Principal Investigators:*

**Russell Pachynski, MD**

Washington University, St. Louis, MO

**Robert Schreiber, PhD**

Washington University, St. Louis, MO

**Goal: Development of a novel immunotherapy for prostate cancer patients that combines an immune-boosting regimen with a patient-specific prostate cancer vaccine**

### 2016 Todd Boehly-PCF Challenge Award

*Principal Investigator:*

**Ramon Parsons, MD, PHD**

Icahn School of Medicine at Mount Sinai Hospital, New York, NY

**Goal: Identification of novel therapies for the treatment of prostate cancer patients whose tumors have mutations in the tumor suppressor genes p53 and/or PTEN**

### 2016 Izzy Englander-PCF Challenge Award

*Co-Principal Investigators:*

**Akash Patnaik, MD, PhD**

University of Chicago, Chicago, IL

**Thomas Gajewski, MD, PhD**

University of Chicago, Chicago, IL

**Walter Stadler, MD**

University of Chicago, Chicago, IL

**Goal: Development of a new precision medicine regimen for patients with PTEN-deficient castrate-resistant prostate cancer that combines a PI3K-inhibitor with checkpoint immunotherapy**

### 2016 PCF VALOR Challenge Award

*Co-Principal Investigators:*

**Matthew Rettig, MD**

UCLA, VA Greater Los Angeles Healthcare System, West Los Angeles, CA

**Bruce Montgomery, PhD**

VA Puget Sound HCS, Seattle, WA

**Goal: Establishment of a precision medicine clinical trial program in the VA Health system and activation of trials that will identify optimal treatments for prostate cancer patients with hereditary mutations in DNA repair genes**

### 2016 Neil DeFeo, Emilio Bassini, and Brent Nicklas-PCF Challenge Award

*Principal Investigator:*

**Karen Sfanos, PhD**

Johns Hopkins University, Baltimore, MD

*Goal: Creation of a gut microbiome biobank as an international scientific resource and determination of whether the gut microbiome affects responses to various prostate cancer treatments*

### 2016 V Foundation-Stewart J. Rahr Foundation-PCF Challenge Award

*Co-Principal Investigators:*

**Eliezer Van Allen, MD**

Harvard: Dana-Farber Cancer Institute, Boston, MA

**Alan D'Andrea, MD**

Harvard: Dana-Farber Cancer Institute, Boston, MA

**Peter Nelson, MD**

Fred Hutchinson Cancer Research Center, Seattle, WA

**Johann de Bono, MD, PhD**

Institute of Cancer Research, The Royal Marsden Hospital, London, England

*Goal: Identification of specific mutations in DNA repair genes that render prostate tumors sensitive to treatment with checkpoint immunotherapy*

### 2016 PCF Special Challenge Awards

#### 2016 Stewart J. Rahr Foundation-PCF Special Challenge Award

*Principal Investigator:*

**Suzanne Conzen, MD**

University of Chicago, Chicago, IL

*Goal: Development of a new therapy for patients with castrate-resistant prostate cancer that targets the glucocorticoid receptor, a protein relative of the androgen receptor that mediates resistance to androgen receptor-targeted therapy*

#### 2016 Stand Up to Cancer-CCPC Special Challenge Award

*Principal Investigator:*

**Martin Gleave, MD**

Vancouver Prostate Centre, Vancouver, BC

*Goal: Development of novel androgen receptor-targeted therapies for prostate cancer patients*

#### 2016 Art Kern-PCF AttackJAK Special Challenge Award

*Principal Investigator:*

**Ross Levine, MD**

Memorial Sloan Kettering Cancer Center, New York, NY

*Goal: Development and validation of JAK2 kinase inhibitors as a novel cancer treatment*

#### Stein Erik Hagen Allmenntytte Stiftelse-PCF Special Challenge Award

*Principal Investigator:*

**Edward Schaeffer, MD**

Johns Hopkins University, Baltimore, MD

*Goal: Identification of genetic and molecular factors that contribute to the development and progression of prostate cancer and can serve as novel therapeutic targets*

#### 2016 Stewart J. Rahr Foundation-PCF Special Challenge Award

*Principal Investigator:*

**Mary-Ellen Taplin, MD**

Harvard: Dana-Farber Cancer Institute, Boston, MA

*Goal: Validation of a novel high-intensity androgen receptor-inhibition strategy as a life-extending and potentially curative treatment for patients with castrate-resistant prostate cancer*



Photography: Paul Bliese

All attendees present at the 23<sup>rd</sup> Annual PCF Scientific Retreat on Friday, October 28, 2016

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

| December 31                             | Unrestricted         | Temporarily Restricted | 2016 Total           | 2015 Total           |
|-----------------------------------------|----------------------|------------------------|----------------------|----------------------|
| <b>ASSETS</b>                           |                      |                        |                      |                      |
| Cash and Cash Equivalents               | \$ 23,725,932        | \$ -                   | \$ 23,725,932        | \$ 28,591,542        |
| Pledges Receivable (Net)                | 21,762,684           | 6,688,362              | 28,451,046           | 24,138,663           |
| Prepaid Expenses and Other Assets       | 203,481              | -                      | 203,481              | 118,578              |
| Property and Equipment (Net)            | 709,738              | -                      | 709,738              | 130,304              |
| <b>Total Assets</b>                     | <b>\$ 46,401,835</b> | <b>\$ 6,688,362</b>    | <b>\$ 53,090,197</b> | <b>\$ 52,979,087</b> |
| <b>LIABILITIES AND NET ASSETS</b>       |                      |                        |                      |                      |
| <b>Liabilities</b>                      |                      |                        |                      |                      |
| Accounts Payable                        | \$ 730,582           | \$ -                   | \$ 730,582           | \$ 263,203           |
| Accrued Liabilities                     | 1,364,526            | -                      | 1,364,526            | 1,309,901            |
| Deferred Revenue                        | 200,000              | -                      | 200,000              | 300,000              |
| Grants Payable                          | 20,442,238           | -                      | 20,442,238           | 21,355,345           |
| <b>Total Liabilities</b>                | <b>22,737,346</b>    | <b>-</b>               | <b>22,737,346</b>    | <b>23,228,449</b>    |
| <b>Net Assets</b>                       |                      |                        |                      |                      |
| Unrestricted                            | 23,664,489           | -                      | 23,664,489           | 25,166,638           |
| Temporarily Restricted                  | -                    | 6,688,362              | 6,688,362            | 4,584,000            |
| <b>Total Net Assets</b>                 | <b>23,664,489</b>    | <b>6,688,362</b>       | <b>30,352,851</b>    | <b>29,750,638</b>    |
| <b>Total Liabilities and Net Assets</b> | <b>\$ 46,401,835</b> | <b>\$ 6,688,362</b>    | <b>\$ 53,090,197</b> | <b>\$ 52,979,087</b> |

# CONSOLIDATED STATEMENT OF ACTIVITIES

| Year Ended December 31                                                   | Unrestricted         | Temporarily Restricted | 2016 Total           | 2015 Total           |
|--------------------------------------------------------------------------|----------------------|------------------------|----------------------|----------------------|
| <b>Revenue and Public Support</b>                                        |                      |                        |                      |                      |
| Grants and Contributions                                                 | \$ 34,973,012        | \$ 6,688,362           | \$ 41,661,374        | \$ 41,047,944        |
| Interest and Dividends                                                   | 39,891               | -                      | 39,891               | 51,342               |
| Other Income (Loss)                                                      | 12,011               | -                      | 12,011               | (76,401)             |
| Net Assets Released from Purpose Restrictions                            | 4,584,000            | (4,584,000)            | -                    | -                    |
| <b>Total Revenue and Public Support</b>                                  | <b>39,608,914</b>    | <b>2,104,362</b>       | <b>41,713,276</b>    | <b>41,022,885</b>    |
| <b>Expenses</b>                                                          |                      |                        |                      |                      |
| <b>Program Services:</b>                                                 |                      |                        |                      |                      |
| Research Grants                                                          | 25,193,943           | -                      | 25,193,943           | 26,933,248           |
| Compensation, Benefits, and Payroll Taxes                                | 3,710,390            | -                      | 3,710,390            | 2,763,999            |
| Global Scientific Conferences, Unpublished Data, and Knowledge Exchanges | 2,175,579            | -                      | 2,175,579            | 1,918,386            |
| Outreach, Events, and Meetings                                           | 920,675              | -                      | 920,675              | 537,496              |
| Professional Fees                                                        | 885,830              | -                      | 885,830              | 813,079              |
| Travel, Meals, and Entertainment                                         | 296,147              | -                      | 296,147              | 228,372              |
| Office Expenses                                                          | 238,009              | -                      | 238,009              | 225,212              |
| Media, Public Relations, and Publications                                | 130,476              | -                      | 130,476              | 1,864,186            |
| Occupancy                                                                | 108,880              | -                      | 108,880              | 117,236              |
| Depreciation and Amortization                                            | 47,313               | -                      | 47,313               | 46,126               |
| <b>Total Program Services:</b>                                           | <b>33,707,242</b>    | <b>-</b>               | <b>33,707,242</b>    | <b>35,447,340</b>    |
| <b>Supporting Services:</b>                                              |                      |                        |                      |                      |
| <b>Management and General:</b>                                           |                      |                        |                      |                      |
| Compensation, Benefits, and Payroll Taxes                                | 1,654,928            | -                      | 1,654,928            | 1,321,694            |
| Office Expenses                                                          | 584,824              | -                      | 584,824              | 534,923              |
| Professional Fees                                                        | 313,759              | -                      | 313,759              | 284,691              |
| Other Expenses                                                           | 311,000              | -                      | 311,000              | -                    |
| Occupancy                                                                | 224,431              | -                      | 224,431              | 202,695              |
| Travel, Meals, and Entertainment                                         | 41,093               | -                      | 41,093               | 45,881               |
| Media, Public Relations, and Publications                                | 35,886               | -                      | 35,886               | 16,923               |
| Depreciation and Amortization                                            | 23,741               | -                      | 23,741               | 33,187               |
| <b>Total Management and General:</b>                                     | <b>3,189,662</b>     | <b>-</b>               | <b>3,189,662</b>     | <b>2,439,994</b>     |
| <b>Fundraising:</b>                                                      |                      |                        |                      |                      |
| Outreach, Events, and Meetings                                           | 1,662,010            | -                      | 1,662,010            | 3,039,745            |
| Travel, Meals, and Entertainment                                         | 1,068,162            | -                      | 1,068,162            | 721,173              |
| Compensation, Benefits, and Payroll Taxes                                | 893,551              | -                      | 893,551              | 720,216              |
| Office Expenses                                                          | 346,623              | -                      | 346,623              | 325,944              |
| Professional Fees                                                        | 190,624              | -                      | 190,624              | 271,672              |
| Occupancy                                                                | 40,662               | -                      | 40,662               | 57,380               |
| Depreciation and Amortization                                            | 9,712                | -                      | 9,712                | 15,812               |
| Media, Public Relations, and Publications                                | 2,815                | -                      | 2,815                | 1,319                |
| <b>Total Fundraising:</b>                                                | <b>4,214,159</b>     | <b>-</b>               | <b>4,214,159</b>     | <b>5,153,261</b>     |
| <b>Total Expenses</b>                                                    | <b>41,111,063</b>    | <b>-</b>               | <b>41,111,063</b>    | <b>43,040,595</b>    |
| <b>Change in Net Assets</b>                                              | <b>(1,502,149)</b>   | <b>2,104,362</b>       | <b>602,213</b>       | <b>(2,017,710)</b>   |
| Net Assets – Beginning of Year                                           | 25,166,638           | 4,584,000              | 29,750,638           | 31,768,348           |
| <b>Net Assets – End of Year</b>                                          | <b>\$ 23,664,489</b> | <b>\$ 6,688,362</b>    | <b>\$ 30,352,851</b> | <b>\$ 29,750,638</b> |

## CONSOLIDATED STATEMENT OF CASH FLOWS

| Year Ended December 31                                                                        | 2016                 | 2015                 |
|-----------------------------------------------------------------------------------------------|----------------------|----------------------|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                                                   |                      |                      |
| Change in Net Assets                                                                          | \$ 602,213           | \$ (2,017,710)       |
| <b>Adjustments to Reconcile Change in Net Assets to Net Cash Used In Operating Activities</b> |                      |                      |
| Uncollectible Pledges Receivable                                                              | 311,000              | -                    |
| Depreciation and Amortization                                                                 | 80,766               | 95,125               |
| (Increase) Decrease in:                                                                       |                      |                      |
| Pledges Receivable                                                                            | (4,623,383)          | 1,956,482            |
| Prepaid Expenses and Other Assets                                                             | (84,903)             | 4,474                |
| Increase (Decrease) in:                                                                       |                      |                      |
| Accounts Payable                                                                              | 467,379              | (876,292)            |
| Accrued Liabilities                                                                           | 54,625               | 321,359              |
| Deferred Revenue                                                                              | (100,000)            | (100,000)            |
| Grants Payable                                                                                | (913,107)            | (552,261)            |
| <b>Net Cash Used In Operating Activities</b>                                                  | <b>(4,205,410)</b>   | <b>(1,168,823)</b>   |
| <b>CASH FLOWS USED IN INVESTING ACTIVITIES</b>                                                |                      |                      |
| Purchase of Property and Equipment                                                            | (660,200)            | (68,523)             |
| <b>Net Decrease in Cash and Cash Equivalents</b>                                              | <b>(4,865,610)</b>   | <b>(1,237,346)</b>   |
| Cash and Cash Equivalents – Beginning of Year                                                 | 28,591,542           | 29,828,888           |
| <b>Cash and Cash Equivalents – End of Year</b>                                                | <b>\$ 23,725,932</b> | <b>\$ 28,591,542</b> |



# INDEPENDENT AUDITOR'S REPORT

To the Board of Directors  
Prostate Cancer Foundation

## Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of the Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2016, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

## Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

## Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Prostate Cancer Foundation as of December 31, 2016, and the changes in its consolidated net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

## Report on Summarized Comparative Information

We have previously audited Prostate Cancer Foundation's 2015 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated April 26, 2016. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2015 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

*Green Hasson & Janks LLP*

April 28, 2017  
Los Angeles, California

# 2016 SUPPORTING PARTNERS

PCF is grateful for our corporate supporters. Contributions and campaigns from these organizations are enabling PCF to move closer to a world without prostate cancer.



Clear Channel  
Outdoor



iHeart  
RADIO

LANDS'END



The REPUBLIC of TEA®



# BOARD OF DIRECTORS AND LEADERSHIP TEAM

## Board of Directors

**Michael Milken**

Founder and Chairman  
Prostate Cancer Foundation

**Andrew J. Astrachan**

Chief Executive Officer  
Onyx Partners, Inc.

**Emilio Bassini**

Managing Principal  
Bassini & Company

**J. Darius Bikoff**

Founder  
The Observatory US, Inc.

**James C. Blair, PhD**

Partner  
Domain Associates, LLC

**Steven A. Burd**

Founder and Chief Executive  
Officer  
Burd Health LLC

**Neil P. DeFeo**

Former Founder and Chairman  
Sun Products Corporation

**David A. Ederer**

Chairman  
Ederer Investment Company

**R. Christian B. Evensen**

Managing Partner  
Flintridge Capital  
Investments, LLC

**Peter T. Grauer**

Chairman  
Bloomberg LP

**The Reverend Rosey Grier**

Milken Family Foundation

**Stein Erik Hagen**

Chairman  
Orkla ASA

**Stuart Holden, MD**

Clinical Professor of Urology  
David Geffen School of Medicine,  
Spielberg Family Chair of Urologic  
Oncology,  
Associate Director, UCLA Institute of  
Urologic Oncology

**Clark Howard**

Syndicated TV and Radio Host

**Arthur H. Kern**

Investor

**David H. Koch**

Executive Vice President  
Koch Industries, Inc.

**Richard S. LeFrak**

Chairman and Chief Executive  
Officer  
LeFrak Organization

**The Honorable Earle I. Mack**

Senior Partner  
The Mack Company

**Shmuel Meitar**

Chairman and Founder  
Aurec Capital

**Lori Milken**

Vice President  
Prostate Cancer Foundation

**Glenn Myles**

Chief Executive Officer  
First Wall Street Family Office

**Henry L. Nordhoff**

Chairman and  
Chief Executive Officer  
Banyan Biomarkers, Inc.

**Drew Pinsky, MD**

Internist, Addictionologist,  
Assistant Clinical Professor,  
Psychiatry  
University of Southern California  
Radio and Television Host

**Lynda Resnick**

Vice Chairman  
The Wonderful Company

**Neal I. Rodin**

Managing Director  
International Financial  
Company

**Jason J. Safriet**

Managing Director  
High Yield and Distressed Sales  
Credit Suisse

**Richard V. Sandler**

Partner  
Maron & Sandler  
Executive Vice President  
Milken Family Foundation

**Jeff C. Tarr, Sr.**

Chairman  
Junction Advisors, Inc.

**Paul Villanti**

Executive Director, Programs  
Movember Foundation

**Andrew C. von Eschenbach, MD**

President, Samaritan Health  
Initiatives Inc.  
Former Commissioner, Food and  
Drug Administration  
Former Director, National Cancer  
Institute  
Senior Fellow, Milken Institute

**Kneeland Youngblood**

Founding Partner  
Pharos Capital Group

**Jeff Zisk**

Managing Director  
Surrey Ventures

## Leadership Team

**Jonathan W. Simons, MD**

President and  
Chief Executive Officer  
David H. Koch Chair

**Ralph Finerman**

Chief Financial Officer,  
Treasurer and Secretary

**John H. Weston**

Executive Vice President,  
Chief Operating Officer

**Howard R. Soule, PhD**

Executive Vice President,  
Chief Science Officer

**Tom Andrus**

Executive Vice President,  
Chief Digital Officer

**Stuart Holden, MD**

Medical Director

**Philip Kantoff, MD**

Chairman, Global Treatment  
Sciences Network, Prostate Cancer  
Foundation  
Chairman of Medicine  
Memorial Sloan Kettering Cancer  
Center

**Helen Hsieh**

Senior Vice President  
Finance and Administration

**Jan Haber**

Vice President  
Events

**Colleen McKenna**

Vice President  
Many vs Cancer



# Prostate Cancer Foundation

Curing Together.




Photo courtesy: Arnie's Army Charitable Foundation

## Arnold Palmer 1929–2016

PCF celebrates the life and contributions of Arnold Palmer, a legend in the world of golf and beyond. We wish to commend him for his 19 years of service as a golf ambassador for PCF. His Arnie's Army Battles Prostate Cancer campaign, benefitting PCF, has resulted in seven \$1 million PCF Challenge Awards, which will ensure the continuity of ground-breaking research breakthroughs for generations to come.

 [facebook.com/PCF.org](https://facebook.com/PCF.org)

 [@PCFnews](https://twitter.com/PCFnews)

1250 Fourth Street, Santa Monica, CA 90401 | 800.757.CURE (2873) | [www.pcf.org](http://www.pcf.org)